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1. Introduction 
 
1.1 Metals in medicine 
Metals have an essential role for processes related to life. Bioinorganic 
Chemistry, the corresponding research field, has experienced emerging interest 
in the past decades.1 As a matter of fact, metal centres have structural, metabolic 
and signalling functions in organisms. For example, it’s been estimated that half 
of all proteins contain metals, most of them being metal-enzymes exploiting the 
catalytic properties of metal centres.  
The idea that metal complexes could have applications in medicine has grown 
mainly after the success of cisplatin (cis-diamminodichloroplatinum(II), 
CDDP) (Figure 1), a Platinum based anticancer drug developed in the late 
1960s.2 
 
 
 
Figure 1. Chemical structure of CDDP. 
 
Currently, Medicinal Inorganic Chemistry has become one of the most 
flourishing research fields of Inorganic Chemistry. As stated by Roger Alberto, 
a Professor of the Institute of Inorganic Chemistry at the University of Zurich 
‘Medicinal inorganic chemistry is a strongly interdisciplinary field. It 
encompasses traditional inorganic and organic chemistry for complex synthesis 
and preparations of tailor- made ligands, (bio)physical chemistry for the study 
of kinetic and thermodynamic properties or interaction of complex- bearing 
pharmacophores with the (macromolecular) targets, biological chemistry for 
vector- drug conjugations or structure activity relationships and biology or 
medicine for in vitro and in vivo testing of the corresponding compounds. 
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Although interdisciplinary, only fundamental understanding of each of these 
scientific building blocks will lead to new metal- based drugs. Contributing 
relevant results out of one of these fields requires broad knowledge and 
understanding of the others, hence, a very attractive opportunity especially for 
young researchers’. 
The richness of coordination chemistry of metal centres, especially transition 
metals, offers enormous chances of tuning reactivity, pharmacokinetic and 
targets of potential metallodrugs. The biological activity of metal compounds 
depends on various characteristics: oxidation state of the metal, geometry and 
number of coordination, type and reactivity of ligands, stability of the nuclide, 
partition coefficient, thermodynamic and kinetic stability3. Moreover, these 
features and thus the reactivity of the compound can vary depending on the 
environment. This aspect is of dramatic relevance in Medicinal Inorganic 
Chemistry, since when developing a potential inorganic pharmaceutic the main 
focus is the in vivo behaviour of the compound and how researchers can predict 
and control this behaviour. A biological environment means physiological pH 
maintained through different buffer systems, thus involving the presence of 
different anions such as phosphates, chloride, carbonates. Moreover, 
biomolecules such as proteins, chelating and redox reactive agents could 
interact with a metal-compound in vivo. Transformations such as ligand 
exchange or hydrolysis, redox reactions at the metal centre or at the ligands are 
responsible of the complex activation in vivo: most of the metal-compounds are 
prodrugs that undergo modification before they reach their target and carry out 
their pharmacological function.4 
Nowadays, only a few metal based drugs are approved for clinical use but many 
others are on clinical or preclinical trials.5 Different medical issues are 
addressed by research on metal-compounds (Figure 2).6,7,8,9,10 Fundamental 
wide-reaching medical problems such as bacterial, viral (particularly HIV), and 
parasitic infections such as malaria are being addressed by research on metal-
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based medicines, mainly involving Silver or Mercury compounds.11,12 
Moreover, Lithium based drugs are used as antidepressives13 and Bismuth 
compounds are antiulcer drugs.14 Platinum anticancer drugs play a fundamental 
role in chemotherapy;15 (alone or in combination with other chemotherapeutic 
agents or radiopharmaceutics. There are also promising developments for 
tackling the main diseases affecting western population: cardiovascular, age-
related inflammatory diseases (e.g., arthritis), neurological diseases (e.g., 
Parkinson’s, Alzheimer’s), cancer,16,17,18 diabetes.19 Metal-based diagnostic 
agents such as Gadolinium(III) complexes,20 for Magnetic Resonance Imaging 
(MRI), and BaSO4 for computed tomography (CT)
21 are in routine clinical use. 
Analogously, 99mTc is the most used radionuclide for Single Photon Emission 
Computed Tomography (SPECT), a diagnostic method based on γ radiation 
emission.22  
 
 
 
Figure 2. Applications of metals in medicine. 
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1.2 Metal-compounds as anticancer agents 
Cancer is a collection of related diseases involving a set of genetic mutations 
causing uncontrolled cell growth, with subsequent invasion of healthy tissues 
and possible spread in other parts of the body through circulatory system, with 
formation of metastasis. Moreover, cancerous cells can replicate infinitely and 
are irresponsive to signals that regulate cellular growth.23 
A chemotherapeutic agent is a cytotoxic compound that kills cancerous cells, 
thus slowing and stopping cancer from spreading. 
The modern era of metal-based anticancer drugs began with the discovery of 
the anticancer activity of CDDP by Barnett Rosenberg in the 1960s.2 Since then, 
CDDP has been used, alone or in combination with other pharmaceuticals, 
against a number of solid tumor types, mainly ovarian, testicular, esophageal, 
head and neck, small cell lung, cervical.24 However CDDP efficacy is hampered 
by poor solubility, narrow therapeutic window, resistance and severe toxicity 
(nephrotoxicity, ototoxicity, neurotoxicity, mielosuppression).25,26,27 
It is generally accepted that cisplatin antitumor profile28 is due to its binding to 
DNA (nuclear and mitochondrial), with distortion of the polynucleotide 
structure. As a consequence, DNA transcription and replication are impaired 
thus inhibiting cell division and eventually causing programmed cell death 
(apoptosis).29 More specifically, CDDP, administered intravenously, is a 
prodrug, activated by mono or di hydrolysis of chloride ligands.30 In blood, it is 
carried mainly by hSA (human Serum Albumin); it is then internalized in cells 
either by passive or active transport. Once in the cells, hydrolysis reaction 
occurs, since the concentration of Cl- drops from a level of about 100mM in 
blood to about 2-30mM in cytoplasm.31 The active species bind DNA through 
crosslinks, being N7 of Guanine (G) the preferred site (Figure 3)32.  
Unfortunately, DNA is not the only target: CDDP binds to many other 
biomolecules involved in cells detoxifying (GSH, Metallothioneines) or other 
proteins manly due to Platinum(II) affinity for thiols.33 These side reactions are 
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responsible for drug inactivation and toxicity. Moreover, the metal-compound 
has low selectivity for cancer cells rather than healthy cells, causing severe 
systemic toxicity over time.34 In addition to this drawbacks, some tumor cells 
either have intrinsic resistance to CDDP or its administration triggers resistance 
pathways such as lower influx and higher efflux of the drug, enhanced efficacy 
of detoxifying mechanisms and more efficient DNA repair pathways, alteration 
of mechanisms that regulate cellular death.35,36 
For all of these reasons, many efforts were made to synthetize 2nd and 3rd 
generation Platinum antitumor complexes with a better compliance, lower 
systemic toxicity and that could overcome cisplatin related resistance 
mechanisms, with efficacy on a broader spectra of cancer types.15 In this 
direction, two novel platinum based anticancer drugs have been worldwide 
approved for clinical use, namely carboplatin (diamine[1,1-
cyclobutanedicarboxylato(2-)-O,O’]platinum(II))37 and oxalilplatin 
([oxalate(2-)-O,O’][1R,2R-cyclohexanediamine-N,N’]platinum(II)).38 Others 
are used regionally (heptaplatin, nedaplatin, lobaplatin) (Figure 4).39 To some 
extents, these compounds have lower toxicity but they have similar mechanisms 
of action and resistance profiles than cisplatin.40 
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Figure 3. Interactions CDDP- DNA: a) CDDP binding site on Guanine; b) possible adducts 
CDDP/DNA. 
 
Figure 4. Platinum based anticancer drugs. 
a) 
b) 
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Although many other metals have been tested in vitro for their cytotoxicity, only 
in a few cases activity in vitro is followed by promising results in vivo. The most 
attractive compounds are those of Ti, V, Fe, Rh, Os, Ln As, Ge, Ga, Ru, Au. 
Notably, two Ruthenium complexes (KP1339 and NAMI-A) and one Gold 
compound (Auranofin) are currently on clinical trials, while preclinical in vivo 
studies on Os, Ti, Gd, La compounds are ongoing. Interestingly, these 
complexes show modes of action that are significantly different from the one of 
CDDP.41 
The most stunning properties concerning Ruthenium coordination compounds, 
are the antimethastatic activity of some of them and the very low toxicity. 
Basically, the most interesting Ruthenium complexes can be divided into three 
classes: Ru(III)-dmso species, ‘Keppler type’ Ru(III) compounds and Ru(II)-
arene complexes. Similarly to CDDP they are regarded as prodrugs activated 
by aquation, in some cases preceded by reduction/oxidation. As a matter of fact 
the so-called ‘activation by reduction’ pathway is often advanced to explain 
Ruthenium complexes mode of action, being the two oxidation states 
Ru(II)/Ru(III) easily accessible under physiological conditions.42 In principle, 
this activation pathway may offer some kind of selectivity against solid tumors 
that have a more reducing environment due to hypoxicity. Another feature often 
invoked to explain selectivity and low toxicity of many Ruthenium compounds 
is the capacity of this metal to mimic iron in binding to many biomolecules, 
including serum proteins (albumin, transferrin).43 However, speciation and 
differences in thermodynamic and kinetic properties should be taken into 
account before assuming an analogy between iron and a Ruthenium compound  
in biological environment.  
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Figure 5. Anticancer Ruthenium drugs: a) NAMI-A; b) KP1019; c) KP1339; d) Ru(II) piano 
stool type compounds developed by Sadler; e) RAPTA-C; f) RAPTA-T. 
 
The first Ruthenium agent to enter clinical trials in 1999 was NAMI-A 
(imidazolium trans-[tetrachloro( dimethylsulfoxide)(imidazole)ruthenate(III)]) 
(Figure 5a).44,45 The drug, is an anionic complex which contains an octahedral 
Ruthenium(III) center bound to an imidazole ligand, with a S-coordinated 
DMSO ligand trans to the imidazole and four chlorides. The DMSO ligand 
confers various chemical features: it’s a good π-acceptor that stabilizes Ru(II) 
facilitating activation by reduction, imparts a good solubility in water and a 
good cellular permeability as well, due to its intrinsic capability to diffuse 
through phospholipidic membranes. In addition, it is a good leaving ligand, thus 
reactive species are expected to form rather easily. At 37°C and pH = 7.4 the 
complex undergoes rapid hydrolysis of two chlorides, process that is believed 
to be responsible for activation of the drug. The reaction is strictly pH 
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dependent, being inhibited at more acidic pH, moreover previous reduction of 
Ru(II) to Ru(III) significantly increases the rate of aquation.46 
Despite its lack of activity against primary tumors, the drug is effective against 
tumor metastases. This is potentially very important because although great 
progresses have been made in treating primary cancers (including surgery, 
chemotherapy, and radiotherapy) secondary metastases represent a major 
clinical challenge. While NAMI-A can bind to DNA, this is not believed to be 
the source of its biological action. The mode of action of this drug is still largely 
unknown but the mechanism of metastatic control seems to be attributable to 
the combined effects of anti-angiogenic and anti-invasive properties of NAMI-
A on cancer cells and on blood vessels.46 The second of the ruthenium agents in 
clinical trials since 2004 belongs to the so-called Keppler type Ru(III) 
compounds: KP1019 (indazolium trans-[tetrachlorobis(1H-
indazole)ruthenate(III)]) (Figure 5b).47,48 Despite its structural similarity to 
NAMI-A, this agent is active against primary tumors, and is being investigated 
for activity against colorectal cancers. The compound causes apoptosis via a 
mitochondrial pathway and is believed to act as a pro-drug, with the actual 
active species not identified yet. Under physiological conditions, activation by 
reduction can occur through reaction with physiologically relevant reducing 
agents (GSH, L-ascorbic acid), followed by metal clusters are not well studied 
as possible anticancer agents yet, as far as I know there are only a few works 
exploring the biological activity of metal clusters.: Dyson et Al report the 
interaction between DNA and charged trinuclear platinum cluster and tri and 
tetranuclear ruthenium clusters.49 Another study of the same author shows 
moderate cytotoxicity of trinuclear ruthenium arene clusters.50substitution of at 
least one chloride ligand with water (or hydroxy) ligands. However, the total 
administrable dose was limited by the relatively poor solubility of the drug, thus, 
its salt analogue KP1339 (Figure 5c) was selected for further developments. The 
reaction with proteins (hAS and transferrin) after intravenous administration 
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appears to be highly relevant for the mode of actin and low toxicity of this class 
of compounds: it could result in an enrichment of the drug in the tumour, 
considering the enhanced permeability and retention (EPR) effect of 
macromolecules and that transferrin receptors are overexpressed on the 
membrane of many cancerous cells.51  
Once inside the cell, these compounds can bind to DNA with a preference 
shown for Guanine and Adenine residues: indeed, it is observed to bind to DNA 
in tumor cells and causes some (though not many) strand breaks, nonetheless 
not so effective at terminating transcription.52 Although DNA might be the 
biomolecular target through which the drug’s cytotoxic activity is revealed, the 
demonstrated and effective binding to protein histidine residues means that 
action via other biomolecules cannot be excluded.  
More recently, another class of ruthenium anticancer agents have been 
developed, whose general structure is [(η6arene)Ru(II)(chel)(X)]n+(figure 5d). 
The class of compounds developed by Sadler and coworkers with chel= en and 
X= Cl- show the most promising properties.53 Mechanistic studies revealed that 
activation occurs through aquation of the chloride ligand and DNA and RNA 
are individuated as the main targets.37 
More interestingly, a series of compounds, namely RAPTA compounds, 
introduced by Dyson and coworkers show an antimetastatic activity.54 The 
general formula of this Ru(II) complexes is [(η6arene)Ru(II)(X)2(pta)] , where 
pta is a posphane monodentate ligand (1,3,5-triaza-7-phosphatricyclo[ 
3.3.1.1]decane) and X can be Cl- or a chelating dicarboxylate. Extensive 
structure-activity relationship studies revealed that the more representative 
compounds of the series are RAPTA-T and RAPTA-C (Figure 5f and 
5e).55,56Also in this case activation is believed to occur with hydrolysis of an 
ancillary ligand X, dissociation of the arene is sometimes observed, while the 
pta ligand is strongly bound to the metal center. Like NAMI-A, these agents are 
inactive against primary tumors but found in vivo to have activity against 
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metastases. The RAPTA complexes are slightly less potent antimetastatic 
agents than NAMI-A, but (in mice) less toxic and thus can be administered in 
higher doses. As NAMI-A, the indications are that proteins, rather than DNA, 
are the biomolecular targets for action of the drug. Given the structural 
differences between the RAPTA and NAMI-A complexes, they might be 
expected to act differently with proteins, perhaps selecting different 
biomolecular targets and pathways.  
Researches are also exploring potentialities of polymetallic complexes. For 
instance, multinuclear Platinum(II) compounds with polyamine linkers 
represent a novel class of antitumor agents.57 One of these species BBR3464 
even entered clinical Phase II but it was not effective in patients with various 
cancers and poorly tolerated, thus trials have been stopped.58 There is emerging 
interest also in the development of polinuclear compounds based on other 
metals59 and of heteronuclear complexes as well.60 
On the contrary, compounds with direct metal-metal bonds are not well studied 
as possible anticancer agents yet. There are only a few works exploring the 
biological activity of metal clusters: Dyson et al report the interaction between 
DNA and charged trinuclear platinum cluster and tri and tetranuclear 
Ruthenium clusters.61 Another study of the same author shows moderate 
cytotoxicity of trinuclear ruthenium arene clusters.62 
 
1.3 The role of Gold 
Gold, relatively rare and chemically inert element, has been a fascinating 
substance throughout history, finding its way into nearly every human culture 
in the form of jewellery, ornaments and monetary exchange. Similarly, the use 
of Gold in medicine, also known as chrysotherapy, has a long tradition with its 
roots in Chinese, Arab, Indian and Egyptian cultures and continues over the 
Middle Age and Reinassance.63,64 In the early times of modern pharmacology 
Gold compounds had various application especially as anti-infective and 
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antitubercular agents. Nowadays, some Gold(I) thiolate species are in clinical 
use for the treatment of severe rheumatoid arthritis (Figure 6).65  
Among these, Auranofin (Figure 6b), a Gold(I) linear complex bearing a 
phosphine and a thio-sugar ligand, is orally administrable and with mild side 
effects. It was developed by Sutton and coworkers in 1980 and approved for 
clinical use in 1985.66 This drug was also the first Gold compound to be tested 
as an anticancer agent: as a matter of fact the connection between cancer and 
arthritis was made years ago when the important anticancer drug 6- 
mercaptopurine was found to have immunosuppressive and anti-inflammatory 
properties, which are the same effects exhibited by antiarthritic agents. This 
finding, together with the success of platinum anticancer drugs, paved the way 
for research on Gold complexes for the treatment of cancer.67 Still no Gold-
based compound is approved for clinical use but there are three active clinical 
trials on Auranofin.68 
 
 
 
Figure 6. Disease modifying antirheumatic drugs (DMARDs): a) Aurothioglucose 
(solganol); b) Auranofin (ridaura); c) Aurothiomalate (myochrisine); d) 
Aurothiopropanolsulfate ( allochrysine); e) Aurobithiosulfate (sanochrysine). 
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The emerging interest in Gold compounds derives from the unique chemistry of 
this metal. The biologically relevant oxidation states are Au(I) and Au(III). 
Au(I) is a ‘soft’ Lewis acid with a d10 closed-shell configuration. For its 
electronic features it has higher affinity for ‘softer’ Lewis bases such has CN-, 
S-donors (RSH, R2S), P-donors and Se-donors rather than N- or O-donors. The 
most frequent coordination geometry is the linear one, but also trigonal or the 
coordinatively saturated tetrahedral geometries are relevant. If no stabilized by 
ligands, Au(I) readily disproportionates into Au(0) and Au(III). Interestingly, 
Au(I) complexes show a pronounced tendency to self-associate: sub-van der 
Waals Au-Au distances of about 3.05 Å indicate the presence of a so called 
‘aurophilic’ interaction with a bond energy comparable to that of standard 
hydrogen bond. Recent computational/theoretical studies indicate that this 
aurophilicity results mainly from dispersion forces reinforced by relativistic 
effects.69  
Au(III), isoelectronic and isostructural to Pt(II), is a d8 metal centre that 
privileges a square planar geometry. It has intermediate HSAB characteristics, 
thus having a considerable affinity for N- and O-donors. These affinities with 
Pt(II) arose the interest in the potentialities of its compounds as anticancer 
agents. The biochemistry of this metal centre is characterized by its strong 
oxidizing properties, so, depending from the degree of stabilization of the 
ligands, it can be in vivo reduced to Au(I) or Au(0). 
Before the mid-1990s there were only a few known Au(III) complexes with 
antitumor activity.70 In general there was a lack of interest in this metal centre 
since Au(III) complexes are not very stable under physiological conditions 
because of their high reduction potential and rate of hydrolysis. However, more 
recently, a range of strategies have been used to stabilize the Au(III) oxidation 
state and various classes of Au(III) compounds have shown significant 
anticancer properties, the most interesting are classical mononuclear Gold(III) 
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compounds, organo-Gold (III) complexes, Gold(III) porphyrins and dinuclear 
species (Figure 7).71 
 
 
 
Figure 7. Some examples of Au(III) anticancer agents: a) [Au(dien)Cl]Cl2; b) 
[Au(cyclam)]Cl(ClO4)2; c) [Au(bipy)(OH)2] PF6; d) Au(DMDT)X2 ; e) Au(damp)X2 (X= Cl, 
malonate, acetate); f) Au(C^N^C)L; g) Auoxo6 ( [Au2(µ-O)2( 6,6- Me2bipy)2]PF6); h) 
Au(TPP)+. 
 
1.3.1 Gold(I) anticancer agents 
As for the current state of art, Gold(I) compounds that show promising 
anticancer properties can be categorized into two classes:72,73 i) neutral, linear, 
two- coordinate complexes, regarded as prodrugs that undergo ligand exchange 
with biomolecular targets and ii) the so called delocalized lipophilic cations 
(DLCs)74,75 whose structure remains intact. For both categories, mitochondria 
are likely targets, with apoptosis induced by alteration of the thiol redox 
balance. On the contrary, these complexes do not usually interact with DNA. 
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The fact that the mechanism of action of these agents is radically different from 
that of CDDP and related platinum compounds renders these species even more 
interesting because they could be able to overcome drawbacks related to CDDP 
induced resistance and hopefully effective toward a different range of tumors. 
Auranofin belongs to the first class of compounds, it was the first to be tested 
in vitro in the late ‘70s and then in vivo. Pharmakokinetic studies indicate that 
this drug undergoes ligand exchange of the thiosugar in presence of thiols or 
selenols, reaction that is responsible of its activation.76 On the contrary, the 
phosphine is bound more tightly and confers lipophilicity and is considered 
important for cellular uptake.76 However, in vivo efficacy of Auranofin and 
related antiarthritic compounds is limited by their high reactivity towards 
thiols.77 These agents are therefore easily inactivated by detoxifying thiol-
donors biomolecules. 
This drawback lead to the development of tetrahedral Au(I)-chelate diphosphine 
complexes, that turned out to be very promising. One of these compounds, 
[Au(dppe)2]Cl (Figure 8a),
78 was candidated to enter clinical trials but was 
halted owing to severe toxicity on heart, liver and lungs attributable to 
mitochondrial dysfunction, identified during toxicological preclinical tests on 
dogs and rabbits.79 Au(I)-chelate diphosphine complexes retain their structure 
in presence of thiols and in human plasma. Their behaviour is consistent with 
that of antitumor agents DLCs.74 [Au(dppe)2]
+ has been proven to enter cancer 
cells and accumulate in the mitochondria driven by elevated mitochondrial 
membrane potential, a characteristic feature of cancer cells.80 In mitochondria, 
it inhibits thioredoxin reductase (TrxR), a selenoenzyme responsible of the 
redox balance of the organelles.81 This triggers mitochondria dependent 
apoptosis pathways.82 The severe toxicity showed by this class of compounds 
was attributed to their high lipophilicity that leads to their unselective 
accumulation in mitochondria, causing general membrane permeabilization. 
Advances have been made designing similar compounds that bear pyridine 
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instead of phenyl substituents on the diphosphine ligand: [Au(dnpype)2]Cl type 
compounds (bearing the N of the pyridine in different positions of the ring) 
(Figure 8b) with a broad range of hydrophilic-lipophilic character have been 
developed.83 They revealed cytotoxicity in vitro that has been related to the 
degree of lipophilicity of the compound. The best profile was found for 
intermediate values of the partition coefficient (logP),84 an indicator of the 
hydrophilic-lipophilic character. The related [Au(d2pypp)2]
+ compound with 
the propyl-bridged 2-pyridyl-phosphine ligand (d2pypp) 85 (Figure 8c) was 
designed with the idea of combining the lipophilic cationic properties that allow 
accumulation into mitochondria and the reactivity toward thiols characteristic 
of Auranofin-like compounds that underlies the inhibition of TrxR. This second 
feature was obtained through easier ligand exchange reactions due to the 
increased chelate ring size. As a matter of fact this compound was shown to be 
selectively toxic to breast cancer cells but not to normal breast cells, to 
accumulate in mitochondria and to selectively induce apoptosis of breast tumor 
cells but not of normal breast cells. Furthermore, it inhibits the activity of both 
thioredoxine (Trx) and TrxR, overexpressed in brest cancer cells in comparison 
to healthy breast cells.85  
To conclude, Gold(I) compounds have been shown to act very differently from 
CDDP: their primary targets are mitochondria and in particular the thioredoxin 
reductase system. However, other possible targets, relevant for their activity, 
can be other classes of proteins such as glutathione peroxidase, cysteine 
proteases, kinases and cathepsines that are characterized by cysteine (Cys) or 
selenocysteine (Sec) aminoacids in the active site. 
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Figure 8. Chemical structures of Au(I) tetrahedral compounds: a) [Au(dppe)2]Cl; b) 
[Au(d2pype)2]Cl; c) [Au(d2pypp)2]Cl 
 
1.3.1.1 Gold(I)-N-heterocyclic carbenes 
More recently, in the light of the uncovered analogies between the coordination 
chemistry of phosphine ligands and Arduengo N-heterocyclic carbenes (NHC), 
new series of compounds have been developed as anticancer agents. Following 
the synthesis of metal-NHC by Öfele and Wanzlick in 196886,87 and the isolation 
of the first free carbene by Arduengo in 1991,88 the use of these ligands in 
homogeneous catalysis dramatically increased.89 NHC, that can be derived from 
imidazole, pyrazole and triazole, are neutral two electron donors with the ability 
to bind both hard and soft metals making them more versatile than phosphines. 
Moreover, not only NHCs are easier to synthetize and functionalize, but they 
also form a stronger Metal-C bond and, therefore, more stable metal 
complexes.90 They interact with metal centres primarily through strong σ-
donation and, to a lesser extent, with π-back-donation. In particular, some works 
by Gosh and coworkers,91 indicate that in Au-NHC complexes π-back-donation 
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was relevant and of a higher degree than in Ag-NHC complexes. This explains 
why Ag-NHC complexes are good trans-metalating agents. 
The first to explore the anticancer potentialities of this kind of compounds was 
the group of Berners-Price, following the success of Gold(I)-phosphines 
complexes; since then, production in this research field flourished.92 The 
possibility of synthesizing compounds with a broad range of structural diversity 
is certainly one of the features that make NHC complexes attractive in drug 
design.  
The great number of moieties studied can be categorized into three classes: 
homoleptic cationic NHC complexes [Au(NHC)2]X; neutral complexes 
[Au(NHC)X] and polinuclear Au(NHC) compounds.93 
Interestingly, lipophilicity of a family of linear cationic Au(I) NHC complexes 
[(R2Im)2Au]
+ has been easily tuned by changing the R substituents.94 Model 1H 
NMR studies with Cys and Sec indicated that release of the NHC ligand occured 
by two-step ligand exchange reactions, with a higher rate for Sec at 
physiological pH. 95 The lead compound [(iPr2Im)2Au]
+ (Figure 9a) was proven 
to selectively accumulate into mitochondria of cancer cells, to cause cell death 
through a mitochondrial apoptotic pathway and to inhibit the activity of TrxR 
but not of the closely related but Se-free enzyme glutathione reductase.95 
Further studies compared [(iPr2Im)2Au]
+ with its neutral analogue (iPr2Im)AuCl 
(Figure 9b): while the cationic compound was selectively cytotoxic toward 
cancer cell lines with a higher mitochondrial membrane potential, the neutral 
compound induced non-selective cell death in all the cell lines tested, suggesting 
a mechanism of action independent from the mitochondrial membrane 
potential.96 The chloride ligand is probable to be readily substituted by thiols or 
selenols of proteins. 
Efforts have been made to understand the differences in the mode of action of 
cationic biscarbene complexes and neutral monocarbene compounds. The first 
ones seem to have an increased antimitochondrial activity owing to charge and 
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lipophilicity, the second ones are usually more potent inhibitors of TrxR 
(cytosolic and mitochondrial) and their activity is dependent on the ancillary 
ligand.97 
Apart from mitochondria and thioredoxin reductase system other protein targets 
have been explored for this class of compounds: for example they have been 
proven to be efficient inhibitors of cysteine dependent protein tyrosine 
phosphatases (PTPs), that are considered targets for several diseases, including 
cancer or autoimmune disorders.98 Furthermore, a recent work described for the 
first time the capacity of a cationic Gold(I) bis-NHC complex containing a 
caffeine-based ligand (Figure 9c) to behave as a DNA G-quadruplex stabilizing 
agent.99 G-quadruplexes are peculiar nucleic acid architectures adopted by 
guanine-rich DNA and RNA sequences, which consist in the stacking of 
contiguous G-quartets. They are an interesting target for anticancer agents since 
they are found in eukaryotic telomeres and in promoter regions of identified 
oncogenes.100 
Interesting is also the possibility of developing of multimodal compounds. For 
example, mononuclear101 and dinuclear,102 luminescent Gold(I)-NHC species 
have been prepared. They showed in vitro cytotoxicity and can be visualized in 
cells through fluorescent imaging.  
Furthermore, as to improve compounds selectivity for cancer cells, a possible 
strategy is to design complexes that are functonalized with a biomolecule that 
is recognized by receptors overexpressed on tumour cells.103 
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Figure 9. Some examples of Gold(I)-NHC compounds a) [(iPr2Im)2Au]Cl; b) (iPr2Im)AuCl; 
c) caffeine based Gold(I) bis-carbene. 
 
1.3.1.1.1 Gold(I)-N-heterocyclic carbenes: synthetic methods 
As already stated, imidazole-derived NHCs are easy to synthesize and 
functionalize.  
The free carbene can be obtained by deprotonation of the correspondent 
imidazolium salt with mild bases such as carbonates (Na2CO3, K2CO3, 
Cs2CO3),
104,105,106 amines107 and acetates108,109 or with strong bases (LiHMDS, 
KOBut, NaOMe, sec-BuLi).110,111 Alternatively, it can be prepared by reaction 
of the imidazolium salt with NaH or KNH2 in liquid ammonia.
112 Less frequent 
methods include the thermolisis of alcohols or chloroform or elimination of C=S 
residues from substituted imidazoles.113,114 Some carbenes are really stable and 
available as ‘bottle-able compounds’: usually they have very bulky substituents 
on the nitrogen. 
Coordination of the NHC ligand to the metal can be achieved by the direct 
reaction between the isolated carbene and a metal precursor or by in situ 
generation of the carbene in the presence of the metal precursor.115The second 
is most frequently used pathway since some carbene ligands can undergo side 
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reactions, such as dimerization.116 Gold(I) precursors used with success for 
these reactions are Au(tht)Cl117,118 (tht= tetrahydrothiophene) and Au(SMe2)Cl 
(Scheme 1, Method A).119  
Another synthetic strategy often reported includes a transmetallation step.115 
First of all the transmetallating agent is isolated and subsequently reacted with 
the Gold(I) precursor (the same reported for the direct reaction) bearing the gold 
NHC carbene quantitatively. Frequently used transmetallating agents are Ag, 
Hg and, to a less extent Cu compounds (Scheme 1, Method B). Transmetallating 
routes usually do not include the use of an external base for the in situ formation 
of the carbene but the deprotonation is operated by basic ligands of the 
transmetallating metal precursor: Ag2O, Ag2CO3, AgNO3, Cu2O are commonly 
used for this step.118,120,121,122,123 The whole synthesis can be usually performed 
in mild conditions, without the need for anidrous conditions and with a good 
compatibility with a broad variety of functional groups. 
 
 
 
Scheme 1. Methods for synthesis of linear and neutral Gold(I)-N-heterocyclic carbenes: 
Method A: direct synthetic route; Method B: transmetalating route. 
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1.4 Methods for the evaluation of biological activity of potential 
anticancer agents 
 
1.4.1 In vitro cell growth inhibition screenings 
As evident from the literature, several cellular targets and pathways may be 
involved in the action of an anticancer compound, but they are, in any event, 
implicated in replicative functions. Therefore, the first approach used to 
evaluate a potential new drug is to measure its cytotoxicity in a cell culture 
assay. The use of human cancer cell lines for the screening of anticancer agents 
gained ground in the late 1980s when the National Cancer Institute (NCI) 
selected 60 cell lines representing nine human tumor types. The NCI-60 panel 
of cancer cell lines was established as a tool for the in vitro screening of 
anticancer drugs.124  
Human cancer cells for these studies are usually grown in a specific cell culture 
medium in an incubator that provides a constant temperature, 37°C, and a 
humified atmosphere containing 5% carbon dioxide, to obviate the loss of water 
and carbon dioxide from the cell culture medium.125 
The composition of the cell culture medium approximates the composition of 
blood  and can vary depending of the cell line cultured, but usually contains 
simple salt and ions (NaCl, Na2HPO4, NaHCO3), the common amino acids, 
various vitamins, glucose, glutathione (GSH) and others. Most of them also 
contain foetal bovine serum (FBS), with a number of proteins important for cell 
growth. In some cases antibiotics are added, to prevent contaminations of 
extraneous microorganisms. To conclude, a small amount of pH-sensitive dye 
is usually present as well, to provide a quick visual check that the pH of the 
medium remains constant during the incubation.126 Studies are usually 
performed in small plastic plates, containing many wells (for examples 96) in 
any of which approximatively the same quantity of cells is cultured. This 
improves the quality of the data, since cell studies are intrinsically ‘noisy’. For 
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cytotoxicity studies the cells are exposed to solutions of the chemotherapeutic 
agent at different concentrations in the cell culture medium. After a fixed time 
(for example 24-72 h) the quantity of live cells is measured. A method to 
evaluate viability it is the so-called MTT assay:127 after growth with the 
cytotoxic agent, medium is substituted by a solution containing an organic 
tetrazolium salt, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
bromide), which is uptaken only by living cells. Once the compound is inside 
the cell, it is bioreduced by NADH with the catalysis of mitochondrial 
hydrogenases to a water soluble formazan salt that has a strong absorption band 
in the visible region of the spectrum. Therefore, the viability of the cell 
population in a well can be determined by measuring the absorption using a 
special plate-reading spectrophotometer and normalizing this value with a 
control, that is the absorption of non-treated cell population. Other methods use 
different dyes such as Sulforodamine B,128 that binds cellular proteins of live 
cells, or Trypan blue129 that can only permeate membranes of dead cells and 
emits fluorescence when bound to DNA. 
The quantity typically reported in cytotoxicity studies is IC50: the concentration 
of toxic agent needed to reduce the growth of a cell population relative to a 
control by 50%.  
 
1.4.2 Ex-vivo toxicity assay 
Toxicity, pharmacokinetics and efficacy of new agents are still extensively 
examined in animals and agencies require compounds to be tested or screened 
in at least one rodent and non-rodent animal model.  
However, efforts have been made to limit the use of in vivo studies for 
preclinical screenings. For example, precision-cut tissue slices (PCTS) are 
widely used by many researchers as an in vitro model of the organ under 
study.130,131 Slices are essentially viable explants of the tissue with a 
reproducible, well defined thickness that can be cultured ex-vivo. They represent 
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a mini-model of the organ because they contain all cell types of the tissue with 
intact intercellular and cell-matrix interactions intact and are, therefore, highly 
appropriate for studying multicellular processes.132 PCTS have been prepared 
from lung, kidney, intestine, brain, heart, prostate, spleen and several tumor 
types. Furthermore, these studies can be applied on animals but also on human 
explanted organs. PCTS are mainly used to study the metabolism and toxicity 
of xenobiotics, but they can also be a model to study of drugs’ uptake, transport 
or efficacy.132  
Slices of solid organs are prepared by making cylindrical cores using a drill with 
a hollow bit. Cores (5-8 mm of diameter) are then sliced with a specially 
designed tissue slicer. Non solid organs or tumors, such as lungs and intestine, 
can be embedded in agarose to form a solid-like organ structure that can be 
sliced. During the slicing process the slicer is filled with a special buffer called 
Krebs-Henseleit (KHB) buffer previously oxygenated with a mixture of 95% 
O2 - 5% CO2. The buffer contains salts and ions (CaCl2, KCl, NaCl, MgSO4, 
KH2PO4, NaHCO3), with supplement of D-glucose and HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid); the pH is 7.42. Before 
incubation, tissue slices can be preserved in ice-cold University of Wisconsin 
organ preservation solution (UW solution). It contains salts (KH2PO4, MgSO4) 
and other substances suitable to keep the tissue healthy (raffinose, adenosine, 
glutathione, allopurinol, hydroxyethyl starch, potassium lactobionate). 133 
Slices are usually cultured in 6 or 12 well plates in a specific medium, the most 
used is the Williams’ Medium E (WME) supplemented with glucose and 
antibiotics; plates are incubated in a dynamic organ culture incubator (DOC) 
that not only keeps the plates under a humified atmosphere with 5% CO2 but 
also shakes them. For toxicological studies, precision-cut tissue slices are 
exposed to various concentrations of the drug in study for a fixed amount of 
time (for example 24 h).132 Afterwards, viability is assessed: a convenient 
marker is the ATP content of each treated slice in comparison to the ATP 
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content of a control, that was incubated without the agent.134 ATP content can 
be measured through a bioluminescence assay: the amount of light produced by 
the ATP consuming reaction catalysed by the natural occurring firefly enzyme 
luciferase is quantified with a luminometer. The amount of light produced is 
directly proportional to the amount of ATP present in the sample. The ATP 
content is normalized for the protein content of each slice to eliminate effects 
due to different slice weights. The total amount of proteins is measured by using 
Lowry assay:135 a colorimetric assay that involves reduction of the Folin–
Ciocalteu reagent and oxidation of aromatic residues (mainly tryptophan, also 
tyrosine) but also cysteine in proteins. 
 
1.4.3 Studies of interactions with DNA 
As to better understand modes of action of antitumor and antiviral drugs 
researchers have been also focusing on the study of the interactions between 
DNA and small molecules.136,137  
DNA is a polynucleotide whose most common structure is the double helix, the 
so-called form B.138 However, DNA can adopt different alternative 
conformations due to particular sequences, to the environment and to 
interactions with proteins.139 These ‘non canonical’ architectures include form 
Z, triple helix (triplex), quadruple helix (G-quadruplex) and play key roles in 
biological processes such as duplication, transcription, apoptosis.140 Many small 
molecules can interact with DNA through different types of non-covalent 
binding. It is possible to distinguish between three types of interactions: external 
binding, groove binding and intercalation (Figure 10). 
External binding of a small molecule to DNA consists in the formation of a 
complex on the external surface of the polynucleotide thanks to electrostatic 
forces.141 Nonetheless, more recently, it was observed that the nature of this 
binding is not purely electrostatic.142 Some intercalating agents give external 
binding as well and the degree of intercalation vs external binding depends on 
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the ratio dye/ polynucleotide.143 Moreover, it is to be considered that in general 
most of the molecules that associate with DNA are positively charged, so 
electrostatic interaction with the phosphate backbone is inevitable.  
 
 
Figure 10. Interactions between DNA and small molecules: a) External binding; b) Groove 
binding; c) Intercalation. 
 
Secondly, groove binding consists in absorption of a molecule in a groove of 
the DNA. Hydrophobic interactions, electrostatic forces and formation of 
hydrogen bonds are involved in this association.142 Hydrogen bonds usually 
form with N3 of adenine or O2 of thymine, therefore interacting agents are often 
found in A/T rich sequences. Capability of a molecule to associate to DNA 
through groove binding is highly dependent on its dimensions and 
conformation;144 it cannot have an excessive sterical hindrance, which would 
prevent it from entering in the grooves of the double helix. 
The third kind of interaction, studied for the first time in 1981 for aromatic 
cations,145 is intercalation: this phenomenon occurs when a planar, aromatic 
molecule with suitable steric features, inserts between two adjacent couples of 
bases, inducing a distortion in the geometry of the polynucleotide. A model to 
explain this process was initially proposed by Lerman.146 This model describes 
the formation of a very stable DNA-dye complex in which stabilization mainly 
depends on -stacking between polynucleotide bases and the dye. Intercalation 
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is also facilitated by a positive charge on the ligand that will be electrostatically 
attracted by the phosphate backbone and insert in the grooves more easily. The 
interaction causes an increase in the distance between the bases of DNA with a 
distortion of helicity compensated by an unwinding of the helix and a 
rearrangement of the sugar-phosphate backbone (Figure 11). The study of 
intercalators-DNA adducts can be important to investigate not only the 
pharmacological but also the toxicological actions of these agents. 
 
 
Figure 11 Model of intercalation: unbound DNA (left); DNA-intercalator adduct (right) 
 
It is important to highlight that all these processes do not involve the formation 
of covalent bonds, which are, on the contrary, formed, for example, when 
CDDP interacts with DNA. Therefore, these are reversible equilibrium 
processes. 
Generally, the binding between DNA and small molecules and related 
thermodynamic and kinetic information, can be investigated through optical 
spectroscopies (spectrophotometric, spectrofluorimetric titrations)142,147 thanks 
to the significant differences between optical properties of the dye alone and 
DNA-dye adduct. Furthermore, also viscosimetric measurements are often 
useful, since conformational changes after association of the polynucleotide 
with a small molecule, result in a significant change of its viscosity.147,148  
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2. Aim of the project 
Following the introduction of platinum based drugs for the treatment of cancer, 
researchers focused on the development of compounds with an improved 
pharmacological profile and an efficacy on platinum resistant tumours.27 
Nowadays, the interest is not only on new platinum based agents but also on 
other metals such as Ruthenium, Gold, Titanium, Osmium and others. Since 
platinum based drugs have many side effects, mainly owing to his high 
reactivity toward inactivating agents and to its poor selectivity for DNA of 
cancerous cells,34 the development of drugs based on other metals is important 
for the discovery of new efficient strategies for cancer treatment. Novel 
delivering strategies of existing drugs have been developed to improve 
selectivity for cancerous cells, the most important characteristic of an antitumor 
drug as to have an enhanced efficacy/side effect profile. In addition to this, 
efforts have been made in designing bioconjugated species that aim at targeting 
specific receptors overexpressed in tumour cells to limit side effects. 
Furthermore, another interesting possibility is the development of multimodal 
theranostic agents that have both imaging and therapeutic functions. 
Aware of all these aspects, in this project we focused on three main objectives 
concerning the study of anticancer properties of a series of organometallic 
compounds. First of all, we focused on the evaluation of the biological activity 
of a series of Gold(I)-N-heterocyclic carbenes and of a platinum cluster. Then, 
the synthesis of a novel Gold(I)-NHC complex with an optimized structure to 
improve the biological activity in comparison to the other compounds studied 
was carried out. Finally the interaction with DNA of representative compounds 
was investigated. 
The compounds under study are a series of Gold(I) N-heterocyclic carbenes 
among which a dinuclear compound and two bioconjugated complexes, and a 
trinuclear Platinum cluster. As a matter of fact Gold(I) NHCs turned out to be a 
promising class of compounds for different reasons: facile synthesis and 
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bioconjugation, tunable lipophilicity and mode of action believed to be 
significantly different from CDDP: their primary targets are usually 
mitochondria and they cause apoptosis by impairing the redox balance of 
tumour cells.72 Interestingly, in vitro selective cytotoxicity of a Gold(I)-NHC 
compound towards cancer cells in comparison to heathy cells has been reported 
in literature by Berners-Price and coworkers.149  
Evaluation of the in vitro antiproliferative effects is a fundamental preliminary 
screening to decide whether a compound can be pharmacologically interesting. 
Therefore, first of all, in vitro cytotoxicity tests were performed on different cell 
lines including a CDDP resistant cell line. Subsequently, the most promising 
agents were also tested ex-vivo on healthy rat tissues to evaluate their toxicity.  
Following the results of biological tests we decided to synthetize a novel 
Gold(I)- NHC complex with an optimized efficacy as an antitumor agent. The 
compound designed should bear both a fluorophore and an alkynyl group on the 
carbene ligand. The fluorophore, an anthracenyl group in this case, makes the 
compound suitable for fluorescence imaging and subsequent localization in 
cells. Whereas, the alkynyl can be easily conjugated with a biomolecule that 
allows more selective targeting of tumour cells and subsequent reduction of 
toxicity. The reaction that allows this functionalization is the “click” reaction 
alkyne-azide Cu(I) catalyzed 1,3 dipolar cycloaddition (CuAAC), often 
employed for this kind of bioconjugations. 150 The other coordination site of our 
lead linear Gold(I) complex is better occupied by an ancillary ligand as to allow 
binding to a possible biological target. 
The organometallic complexes under study were characterized by 1H and 
13C{1H} NMR, FT-IR, X-Ray diffractometry and UV-Vis spectrophotometry. 
Finally, preliminary investigations on possible targets included studies of 
interaction of the newly synthetized Gold(I)-carbene and of the platinum 
trinuclear cluster with CT-DNA by means of fluorimetric titration or 
 
 
35 
 
viscosimetry. This part of the project was carried out in collaboration with Dr. 
Tarita Biver of University of Pisa. 
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3. Results and discussion 
 
3.1 Evaluation of the biological activity of organometallic compounds 
This part of the project was carried out during my six months Erasmus 
traineeship period at the Faculty of Pharmacy (Department of Pharmakokinetic 
Toxicology and Targeting) of University of Groningen under the supervision of 
Prof. Angela Casini. As discussed previously, the aim of this work was to 
evaluate the biological activity of a series of organometallic compounds and in 
particular their potentialities as anticancer agents. 
The in vitro antiproliferative effects of the selected compounds in Figure 13 and 
14 were assessed through MTT assay after 72 h incubation at 37°C.  
The compounds under study are all Gold(I)-NHCs except for 4 which is a 
trinuclear platinum cluster with 3 terminal CO ligands and 3 µ2-bridged 
phosphides (Figure 12 and 13). This cluster has been synthetized by the group 
of Prof. Piero Leoni.151,152 Moreover, its spectroscopic and electrochemical 
properties have been explored153,154 as well as its use as a building block for 
more complex structures.155 However, possible biological applications had not 
been investigated yet. In the literature there are only a few examples of metal 
clusters that show in vitro activity. For example Dyson and coworkers reported 
the in vitro antiproliferative activity of trinuclear ruthenium clusters, as well as 
the interaction with DNA of trinuclear platinum and tri and tetranuclear 
ruthenium clusters.49,50 
One of the compounds examined, 5, has been previously synthetized in the 
research group of Prof. Chiara Gabbiani following a procedure reported in 
literature.156 This compound bears a bulk NHC ligand and an alkynyl ligand: it 
was designed to be furtherly functionalized with peptides (CIA(Z), MTIIN3). 
5-CIA(Z) and 5-MTIIN3 were prepared in collaboration with the group of Prof. 
Luigi Messori of University of Florence. 5-CIA(Z) is functionalized with 
dicarbaoctreotide, an octapeptide which mimics the pharmacological function 
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of somatostatine. Somatostatine is a cyclic peptide that binds receptors 
overexpressed in some type of cancerous cells whose main function is to release 
the growth hormone. A pharmacological analogue of somatostatine is 
octreotide157 (Figure 14a) a cyclic octapeptide with a disulfure bridge, 
dicarbaoctreotide158 (Figure 14b) bears a double C=C bond in substitution of the 
sulfur bridge. The other peptide used is MTIIN3:159 a cyclic heptapeptide, 
agonist of melanocortine receptors functionalized with an azide functional 
group as to directly react with the alkynyl ligand of 5 through a CuAAC click 
reaction.150 
 
 
Figure 12. Chemical structure of some of the compounds under study: 1, 2, 3, 4. 
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Figure 13. Chemical structure of some of the compounds under study: 5, 5-CIA(Z); 5-
MTIIN3; CIA(Z); MTIIN3. 
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Figure 14. a) Chemical structure of octreotide; b) chemical structure of dicarbaoctreotide. 
 
Other compounds tested were 2 and 3, previously synthetized by our group:160 
2 is a linear monocarbene while 3 is a cationic biscarbene, this structural 
difference could result in different biological activity.96 In previous studies they 
showed comparable and potent cytotoxic activity toward both A2780/S and 
A2780/R, ovarian cancer cell lines respectively sensitive and resistant to 
cisplatin.160 The other compound tested was 1, a newly synthetized analogue of 
Auranofin whose preparation is presented in this work, bearing the same NHC 
ligand as 2,3 and a thiosugar as ancillary ligand. Similar compounds had already 
been reported by Berners-Price.161 
The cytotoxicity of the complexes in comparison to CDDP was evaluated on 
different types of tumour cells: MCF-7 an epithelial-like breast adenocarcinoma 
cell line, poorly sensitive to CDDP;162,163 A375 epithelial malignant melanoma 
cells characterized by a rapid growth and two colorectal adenocarcinoma cell 
lines HCT116 p53 +/+ (wild type p53) and HCT116 p53 -/- (null p53). It has 
been shown that in this cell lines CDDP causes apoptosis through p53 dependent 
pathways.164 Therefore HCT116 -/- ,that have no active p53 are intrinsically 
more resistant to CDDP. p53 is a key protein for the body to fight cancer.165,166 
It is a transcription factor involved in various pathways: cell-cycle inhibition, 
triggering of apoptosis, inhibition of blood vessels formation, genetic 
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stability.167 In many cancer cells p53 gene is inactivated or the protein is 
inhibited with subsequent uncontrolled growth of tumour cells.165 
MTT assay showed that the active compounds have a moderate high 
cytotoxicity with IC50 values ranging from 0.1 to 10 µM and are in general more 
cytotoxic than CDDP (Figure 15, Table 1). Compounds with IC50 values higher 
than 50 µM are considered inactive. As expected, CDDP showed a remarkable 
difference in the inhibition of HCT116 p53 +/+ and -/- cell lines growth with 
IC50 values of 12 µM and 20.6 µM respectively. The most active compounds 
are 1, 2 and 3, these last two complexes showed IC50 values comparable to that 
found on other cell lines.160 These compounds are unselectively cytotoxic 
towards all the cell lines under study. The lack of significantly different effects 
on HCT116 +/+ and -/- indicates that, differently from the mode of action of 
CDDP, the biological activity of these compounds is not related to p53 
expression. This could represent an advantage in overcoming cisplatin related 
resistance mechanisms.  
The bioconjugated compound 5-CIA(Z) was found to be inactive toward 
HCT116 +/+ and MCF-7 with an IC50 > 50µM. This result could be ascribed to 
the fact that dicarbaocreotide, as somatostatine, is not uptaken by cells, it only 
binds membrane receptor. Therefore if the ancillary tetrazolium ligand is not 
released the complex cannot get in the cell.  
Better results (IC50= 16± 6 µM) were found for 5-MTIIN3, tested on HCT116 
+/+ in comparison to the peptide MTIIN3, not cytotoxic. 
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a The reported values are the mean ± SD of at least three determination. 
 
Table 1. Summary of IC50 values of the compounds studied against different human tumour 
cell lines. 
 
 
 
IC50a (µM) 
 
  Cell line HCT116 p53 +/+   HCT116 p53  -/-   MCF-7   A375    
Compound 
         
 
1 
 
0,8± 0,2 
 
1,4± 0,4 
 
2,4± 0,8 
 
1,2± 0,2 
 
 
2 
 
0,5± 0,3 
 
0,6± 0,2 
 
0,82± 0,45 
 
2± 1 
 
 
3 
 
0,6± 0,4 
 
0,2± 0,1 
 
1,1± 0,3 
 
1,0± 0,6 
 
 
4 
 
9± 4  
 
10± 3 
 
3,1± 0,7 
   
 
5 
 
9± 3 
 
9± 1 
 
6,5± 2,1 
   
 
5-CIA 
 
>50  
   
>50  
   
 
CIA(Z) 
 
>50 
       
 
5-MTIIN3 
 
16± 6 
       
 
MTIIN3 
 
>50 
       
 
CDDP 
 
12± 3 
 
20,6± 0,9 
 
12 ± 2 
 
3,7± 0,9 
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Figure 15. IC50 values of studied compounds against various cancer cell lines compared to 
CDDP after 72 h incubation at 37°C.  
 
The most active compounds 1, 2, 3 were selected for ex-vivo toxicity studies 
using Precision Cut Kidney Slices (PCKS). Tests on CDDP were used for 
comparison. These kind of experiments have been extensively studied by the 
research group of Prof. Geny Groothuis.132,133 Precision Cut Tissue Slices, 
viable explants of tissue with a reproducible thickness, represent a convenient 
method to evaluate the toxicity of a drug, that involves multicellular processes. 
Since they contain all cells of the tissue in their natural environment with intact 
cell-matrix interactions, thus they represent a mini-model of the organ under 
study. 
Since the most severe and dose limiting side effect of cisplatin is 
nephrotoxicity168,169 we chose kidney as the model healthy organ to have an idea 
on the specificity of our compounds for cancer cells over healthy ones if 
compared to CDDP.  
PCKS have been used to study molecular mechanisms involved in cisplatin 
related nephrotoxicity170 and for investigations on the toxicity of palladium 
cages with encapsulated CDDP.171 Nonetheless, the study of the toxicology of 
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gold based compounds is still at the beginning and the use of PCTS model to 
evaluate the toxicity of Gold(I)-NHC has been reported only by Prof. Angela 
Casini and coworkers, as far it is known.99 
In the present work slices have been incubated with the compounds for 24 h at 
37°C. Viability has been evaluated by measuring the ATP content of the slices 
and comparing this value with the ATP content of non-treated slices. The ATP 
content was normalized for the protein count.  
Results revealed that the tested complexes are remarkably toxic already at 
concentrations lower than 5 µM with viability of tissue dropping to less than 
20% in comparison to the control (Figure 16). Whereas, CDDP reduces the ATP 
content to less than the 20% of the control only at 50 µM concentration. For 
each compound resulting IC50 values were calculated as mean value of at least 
three experiments (Table 2). The IC50 value for CDDP was 16 µM versus IC50 
values for the Gold(I) carbenes ranging from 0.8 to 2.1 µM. Although the toxic 
effects of the Gold(I) compounds appear at least one order of magnitude lower 
in concentration, analogously this species showed to be cytotoxic toward human 
cancer cell lines at about 10-fold minor concentrations in comparison to 
cisplatin. 
Notably the cationic biscarbene 3 showed toxicity comparable to the neutral 
monocarbene 2. This is in contrast with what was found in a previously reported 
work that showed that a cationic biscarbene was toxic on kidney slices only at 
concentrations 10-fold higher than the monocarbene.99 Behaviour of compound 
3 cannot be related to that of DLCs that selectively accumulate in mitochondria 
of cancerous cells.74,75 
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Figure 16. Graphs of viability % of PCKS in comparison to controls after 24 h at 37°C 
exposure to different concentrations of the compounds.  
 
  IC50 (μM) 
CDDP 16 ± 2 
1 2.1 ± 0.4 
2 0.8 ± 0.3 
3 1.5 ± 0.1 
 
Table 2. Summary of IC50 values of the compounds tested against PCKS. 
 
3.2 Synthesis of new Gold(I)-NHC complexes 
As already mentioned, another objective of this project was the synthesis of 
novel Gold(I)-NHC compounds with anticancer potentialities. In the first 
compound prepared Gold(I) centre is coordinated a NHC and a thiosugar 
ligands. This complex is a new analogue of Auranofin, the antiarthritic drug 
first to be tested as anticancer agents.66 Studies on Auranofin showed the 
primary importance of the thiosugar ancillary ligand for the biological activity, 
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while the phosphine was considered important for uptake in cells.172 
Coordination chemistry of NHC-carbenes has shown similar features to that of 
phosphine;89 therefore these ligands have found many applications in 
catalysis.173 Indeed, NHCs form stronger metal-C bonds and are easy to 
synthetize and functionalize.174 Researchers, first of all Berners-Price and 
coworkers, have also explored thei applications of Gold(I)-NHC organometallic 
compounds as anticancer agents,175 with the aim of improving the 
pharmacological profiles of Gold(I) phosphines. We considered interesting to 
synthetize a novel analogue of Auranofin bearing a NHC ligand in substitution 
of the phosphine. We chose the same NHC as compound 2 and 3 since these 
compolexes already showed good cytotoxicity. Preparation of similar analogues 
of Auranofin bearing NHC ligands had already been reported.161,176.  
Another part of the work, performed in collaboration with the group of Prof. 
Luigi Messori of University of Florence, aimed at preparing new dicarba- 
analogues of somatostatine bound to metal-complexes. As already mentioned, 
somatostatine is a biomolecule that binds receptors overexpressed in some type 
of cancerous cells whose main function is to release the growth hormone. The 
idea is to covalently bind dicarba-ocreotide,158 to the carbenic Gold(I) complex. 
Following the results of biological activity studies discussed in the previous 
paragraph and in particular the finding of the low biological activity of 
bioconjugated derivatives of 5, we decided to design a new compound that 
could be furtherly bioconjugated. We decided to change the carbenic ligand 
with one bearing both a fluorophore that would allow fluorescence imaging in 
cells and a group that could be furtherly bioconjugated to a peptide to selectively 
target receptors overexpressed on cancer cells. A convenient pathway for the 
bioconjugation at the periphery of ligand bound to metal ions is the Cu(I) 
catalysed alkyne-azide 1,3 dipolar cycloaddition (CuAAC) (Scheme 2).150,177 
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Scheme 2. General scheme of a CuAAC reaction. 
 
Thus, our lead compound had to be designed with an alkyne. In the case of 5-
MTIIN3 and 5-CIA(Z) bioconjugation resulted in inactivation of biological 
activity of 5. As a matter of fact, since the peptides cannot enter the cells, if the 
ligand is not exchanged in vivo, owing to a strong Gold(I)-triazole bond, 
compounds 5-MTIIN3 and 5-CIA(Z) cannot enter the cells either. Moreover, 
one of the reasons why Gold(I)–alkynyl complex 5 displayed only a moderate 
in vitro could be the strength of Gold(I)-alkynyl bond that renders this 
compound inert toward ligand exchange reactions in vivo, necessary for its 
binding to possible biological targets. Therefore, in the new designed complex, 
we decided to bind the alkynyl functional group to the N-heterocyclic ligand 
(that could be an imidazole or a benzimidazole) instead that directly to the 
Gold(I) centre. Subsequently octreotide can be bound through formation of a 
peptide bond between a terminal carboxylic group on the triazolium linker of 
the Gold(I) carbene and the amine group on the phenylalanine residue of the 
octapeptide. This synthetic strategy has already been used in the group of Prof. 
Luigi Messori for the preparation of 5-CIA(Z), 5-MTIIN3 and in another 
reported work on similar substrates. 178 This time the other coordination site was 
occupied by a labile ligand to facilitate binding of the Gold(I) center to the 
eventual biological target. As for the fluorophore, we chose to bind the NHC 
ligand to a methyl-anthracenyl group. Indeed, a work reported in literature by 
Prof. Angela Casini, showed cytotoxicity and in vitro fluorescence imaging of 
a Gold(I)-NHC complex bearing the same fluorophore.101  
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In theory, our target compound could be prepared easily from the 
correspondents imidazolium (or benzimidazolium) salts by following the well 
explored synthetic procedures already mentioned in the Introduction and 
reported in Scheme 3.115 
Figure 17 shows the chemical structure of the compounds we sought to 
synthetize. 
 
 
Scheme 3. General synthetic scheme of Gold(I) carbenes. 
 
 
 
Figure 17. Chemical structure of compounds designed for synthesis. 
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3.2.1 Synthesis of thio-β-D-glucose-tetraacetate-(1-butyl-3-methyl)-
imidazol-2-ylidene-Gold(I) (1) 
Complex 1 is an analougue of Auranofin. The compound was obtained in high 
yields (95 %) by adapting a procedure previously published by Baker et Al. for 
the synthesis of similar Gold(I)-NHC complexes161 that allows the substitution 
of a chloride ligand using K2CO3 in CH2Cl2 in presence of the thiosugar 
(Scheme 4). The precursor used was 2, whose preparation has already been 
reported by us.160 The novel compound, stable to air and moisture, was found 
to be well soluble inmost of the organic solvents.  
1 was characterized in solution by 1H and 13C{1H} NMR in CDCl3 and in the 
solid state by FT-IR. 
Signals in NMR spectra are consistent with the ones expected for similar 
compounds.161 
The most diagnostic feature in 13C{1H} NMR spectrum is the carbene carbon 
signal at 183.7 ppm. This signal is downfield shifted if compared with the signal 
in the correspondent precursor 2 that resonates at δ = 171.9 ppm.160 This feature 
could be probably explained with the more π-acidity of the thiolate ligand of 1 
than the chloride ancillary ligand of 2.179,180 The carbon bound to the thiolate 
group resonates at lower fields than the one in the uncoordinated ligand: it shifts 
from 78.9 ppm to 83.0 ppm after coordination to the Gold(I) centre. In 1H NMR 
spectrum the coordination of the thiolate is confirmed by the absence of the S-
H resonance at δ = 2.31 ppm.  
In FT-IR spectrum the most diagnostic feature is the band of the carbonyls at ν 
= 1744 cm-1.  
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Scheme 4. Synthesis reaction of 1. 
 
3.2.2 Synthesis of 1-(9-anthracenylmethyl) imidazole (6) 
Preparation of this N-substituted imidazole was already reported in literature:181 
generally imidazole was treated with NaH in 1,4 dioxane and reacted with 9-
chloromethylanthracene. However, we synthetized this compound adapting 
another known procedure that involved the use of K2CO3 as base in DMF 
(Scheme 5).182 After 12 h stirring at 50°C the reaction was quenched with water 
and the mixture was extracted with CH2Cl2. A yellow side product was 
separated from the organic phase by precipitation with Et2O and subsequent 
filtration. It was analyzed by 1H NMR and identified as the disubstituted 
imidazolium salt. The most characteristic signal in this spectrum was the acidic 
proton (NCHN) at δ = 11.82 ppm, typical of imidazolium salts, significantly 
downfield shifted in comparison to the imidazole. 
Compound 6 was obtained as an orange solid in moderate yields (45%) from 
the organic phase by removing the solvent under reduced pressure. The product, 
stable to air and moisture, was characterized by 1H and 13C{1H} NMR in CDCl3. 
Signals are consistent with the ones previously reported.181 In 1H NMR 
spectrum the characteristic signals are those of the protons of the central phenyl 
ring in the anthracenyl moiety, a singlet at δ = 8.57 ppm, and the singlet of the 
methylene group bound to the anthracenyl at δ = 6.07 ppm, downfield shifted 
in comparison to the signal in 9-chloromethyl-anthracene (δ = 5.53 ppm). In 13C 
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NMR spectrum the four signals of the eight CH of the side phenyl rings of the 
anthracenyl (δ = 129.7; 127.5; 125.4; 123.0 ppm) and the one of the methyl 
group bond to the anthracenyl moiety (δ = 43.4 ppm) are well recognizable for 
chemical shift and intensity. 
 
 
Scheme 5. Synthesis reaction of 6. 
 
3.2.3 Synthesis of 1-(9-anthracenylmethyl)3-(4-butynyl)imidazolium 
bromide (7) 
Synthesis of this imidazolium salt had not been reported yet. We followed a 
procedure that described N-functionalization of a benzyl-imidazolium with 4-
bromo-butyne to bear the correspondent imidazolium bromide, by refluxing 
these reagents in toluene for 3 days (Scheme 6).183 In our case imidazole 6 and 
a slight excess of 4-bromobutyne in toluene were allowed to reflux for a week. 
Over time, 7, a white solid, precipitates from the reaction mixture but it is 
obtained with low yields of 20 %. One of the reasons for the low yields could 
be the decomposition of the alkyne after a prolonged time at the high reaction 
temperature.  
The imidazolium salt is stable to air but quite hygroscopic. It is moderately 
soluble in chlorinated solvents and DMSO. The product was characterized by 
1H and 13C{1H} NMR. 
Owing to the positive charge on the imidazolium salt, the signal of the acidic 
proton in 1H NMR spectrum (δ = 10.96 ppm) are at lower fields than in the 
spectrum of precursor 6 (δ = 7.62-7.47 ppm). The same happens to the signal of 
the methylene bound to the anthracenyl moiety that shifts from 6.07 ppm in 6 
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to 6.62 ppm. The signals of the butynyl protons and in particular the terminal 
alkynyl proton, a triplet at 1.98 ppm (3J = 2.3 Hz) due to long range coupling 
with the methylene in α to the triple bond are characteristic as well. In 13C{1H} 
NMR spectrum the diagnostic signals of the carbon between the two nitrogens 
(δ = 137.7 ppm) and of the methylenic carbon in α position to the anthracenyl 
(δ = 46.0 ppm) experience a slightly downfield shift in comparison to compound 
6 (δ =136.8; 43.4 ppm respectively). 
 
Scheme 6. Synthesis reaction of 7. 
 
3.2.4 Attempt to synthetize 1-(9-anthracenylmethyl)3-(4-butynil)-imidazol-
2-ylidene Silver Bromide (8) 
We wanted to synthetize the Gold(I)-NHC monocarbene of 7 through a 
transmetalating route with Ag2O, one of the most common transmetalating 
agent for the synthesis of Gold(I) NHCs.115 We used a mixture of 
CH2Cl2/MeOH (3:1) as solvent to dissolve 7 completely (Scheme 7). The use 
of MeOH was already reported by us for the synthesis of 2.160 After 1 day 
stirring at room temperature the reaction mixture was filtered over Celite and 
the solvent was removed from the filtrate under reduced pressure. 1H NMR 
spectrum in CDCl3 of the light yellow solid obtained showed that the precursor 
was still present and other two species were formed. Another attempt to prepare 
7 with longer reaction times (4 d) gave a dark mixture. The reaction mixture 
was filtered over Celite and the filtrate was dried under reduced pressure. 1H 
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NMR spectrum of the solid obtained in DMSO showed that it was composed by 
many species, probably decomposition products of the reagents. 
 
Scheme 7. Scheme of the reaction expected to bear product 8. 
 
3.2.5 Attempts to synthetize 1-(9-anthracenylmethyl)3-(4-butynil)-
imidazol-2-ylidene Gold Chloride (9) 
After the failed attempt to prepare 8 we sought to synthetize the Gold(I) 
complex 9 directly from the imidazolium salt. 
A simple procedure to bear 9 by in situ deprotonation of the imidazolium salt 
with a large excess of K2CO3 in CH2Cl2 in presence of AuCl(SMe2) was reported 
in literature (Scheme 8).184 After filtration of the reaction mixture on Celite, a 
solid was precipitated by adding Et2O. The white solid, recovered by filtration 
was analyzed by 1H NMR in CDCl3. The spectrum showed the presence of a set 
of signals ascribed to the precursor, recognizable by the diagnostic signal of the 
acidic proton at low-fields (δ = 10.16 ppm) and of the methylenic group in α of 
the anthracenyl moiety (δ = 6.64 ppm). At least another set of signals with a 
deshielded proton at δ = 9.67 ppm, was individuated, which, however, is not 
consistent with formation of product 9. Furthermore, the solid appeared to be 
very sentitive to air, moisture and/or light, turning greenish and getting oily after 
few hours. The filtrate was dried under reduced pressure and the solid obtained 
was analized by 1H NMR in CDCl3. Also in this case the set of signals of the 
precursor could be individuated. Other signals could not be ascribed to 9. 
7 8 
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Scheme 8. Scheme of the reaction expected to give 9. 
In light of the failed attempt to synthesize 9 we decided to change the lead 
compound in order to improve the solubility of the N-heterocyclic salt and the 
stability of the correspondent metal complexes. Some issues concerning the 
stability and the purification of similar Silver(I) and Gold(I)-NHCs were also 
encountered by Garner et al..183 The same work reports the stabilization of the 
metal complexes by substituting imidazole with benzimidazole in the NHC 
ligand. Moreover, another problem of the failed carbenic complexes preparation 
could be the deprotonation of the terminal alkynyl under basic reaction 
conditions. Therefore, we sought to coordinate Gold(I) to a benzimidazol-
ylidene functionalized with the same methylanthracenyl moiety and with an 
alkynyl bearing a terminal trimethylsilyl protection group.  
 
3.2.6 Synthesis of 1-(9-anthracenylmethyl)benzimidazole (10)  
Synthesis of 10 had already been reported in literature: it involved the reaction 
between benzimidazole and 9-chloromethylanthracene in dry THF using the 
base NaH with a yield of 64%.185 We prepared the compound with higer yields 
(82%) in DMF using K2CO3 as base following the same procedure used for the 
synthesis of 6 (Scheme 9).182 In this case we selectively obtained the product 
without the side formation of the disubstituted benzimidazolium salt. 
Compound 10, stable to air and moisture, was characterized by 1H and 13C{1H} 
NMR in DMSO d6. In 
1H NMR spectrum the characteristic signal is the singlet 
7 
9 
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of the methylenic group bound to the anthracenyl moiety at δ = 6.45 ppm, 
downfield shifted in comparison to 6 where it resonates at δ = 6.07 ppm and to 
the reagent 9-chloromethyl-anthracene where it goes at δ = 5.53 ppm. 
Analogously, signals in 13C{1H} NMR are consistent with data reported in 
literature.186 
 
 
Scheme 9. Synthesis reaction scheme of 10. 
 
3.2.7 Synthesis of 1-(9-anthracenylmethyl)3-(1-trimethylsilyl-3-propynil) 
benzimidazolium bromide (11) 
We synthetized the benzimidazolium bromide 11 by adapting a known 
procedure used for similar substrates (Scheme 10).183 Initial attempts were 
carried out in toluene but, similiarly to the preparation of 7, the reaction required 
long times and gave very low yields. Another procedure for the further 
functionalization of mono N-substituted imidazole to bear hetero-disubstituted 
imidazolium salts reported the use of CH3CN as solvent.
187 If we hypothesized 
an SN
2-like mechanism for the reaction, the use of a polar aprotic solvent could 
favour the reaction. However, 10 was found to be insoluble in this solvent. 
Eventually, the reaction was carried out in DMF at 40°C for 3 days giving 11 
in good yields (74%). The product was isolated after precipitation from the 
reaction mixture with Et2O. It was furtherly cleaned by slow precipitation after 
cooling down (-20°C) from a concentrated solution in CH2Cl2. The 
microcrystalline solid, stable to air and moisture, was characterized in the solid 
state by FT-IR and in solution by 1H and 13C{1H} NMR in CDCl3. 
1H NMR 
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spectrum shows the relevant downfield shift of the acidic proton NCHN (δ = 
11.20 ppm) in comparison to 10 (δ = 7.78 ppm in DMSO d6) due to the positive 
charge on the benzimidazole. Analogously, also the methylene bound to the 
anthracenyl moiety is more deshielded and resonates at δ = 6.82 ppm. The 
singlet of the methylene of the propynyl residue (δ = 5.52 ppm) and the singlet 
attributable to the three methyls of the terminal -SiMe3 group (δ = 0.08 ppm) 
are characteristic as well. 
Similiarly, in 13C{1H} NMR the characteristic signals of the carbon between the 
two nitrogen and of the methylene carbon bound to the anthracenyl moiety are 
deshielded in comparison to 10. Other diagnostic signals are those of the 
quaternary carbons of the triple bond (δ = 95.3, 94.5 ppm), of the methylene 
group of the alkynyl (δ = 39.1 ppm) and the shielded signal of the methyl groups 
on the –SiMe3 residue (δ = -0.5 ppm) 
In the FT-IR spectrum the most characteristic feature is the stretching of the C-
C triple bond at ν = 2190 cm-1. 
 
Scheme 10. Synthesis reaction scheme of 11. 
 
3.2.8 Synthesis of 1-(9-anthracenylmethyl)3-(1-trimethylsilyl-3-propynil)-
benzimidazol-2-ylidene Silver bromide (12) 
The Ag(I)-NHC 12 was prepared according to commonly used pathways that 
involve the reaction of the imidazolium salt with an excess of Ag2O in CH2Cl2 
(Scheme 11). 183,188 
11 
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After filtration of the reaction mixture on Celite to eliminate Ag2O in excess 
and a grey side product formed during the reaction, solvent was removed under 
reduced pressure and the product was obtained in low yields (36%). It was stable 
to air and moisture but, as precaution, it was protected by light. The Silver(I) 
compound was characterized by 1H and 13C{1H} NMR in CDCl3. In 
1H NMR 
spectrum the absence of the acidic proton at high chemical shifts is diagnostic 
for the formation of the product. In comparison to 11, the signal of the 
methylenic group bound to the anthracenyl moiety experiences a significant 
upfield shift from δ = 6.82 ppm to δ = 6.36 ppm. In 13C{1H} NMR spectrum the 
most diagnostic signal is the one of the sharp singlet of the carbenic carbon that 
resonates at high chemical shifts (δ = 191.5 ppm) with a relevant downfield shift 
in comparison to the same carbon in 11 (δ = 142.2 ppm). The chemical shift of 
the carbenic carbon is consistent with the one reported for similar 
compounds.101,183 The absence of coupling 107,109Ag-13C indicates a fast 
exchange of the NHC ligand, making the complex a good transmetalating agent 
for the synthesis of the Gold(I) complex.188,189 
The presence of the protection group -SiMe3 on the alkinyl is confirmed by the 
signal at chemical shift around zero (δ = -0.2 ppm). 
 
 
 
Scheme 11. Synthesis reaction scheme of 12. 
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3.2.9 Synthesis of 1-(9-anthracenylmethyl)3-(1-trimethylsilyl-3-propynil)-
benzimidazol-2-ylidene Gold Chloride (13) 
The transmetalation step was carried out according to the common procedure 
frequently cited in literature that requires the use of AuCl(SMe2) as Gold(I) 
precursor in CH2Cl2 and protection from light (Scheme 12).
119 The 
transmetalation is confirmed by the formation of a white solid (AgBr). After 
filtration of the reaction mixture on Celite and precipitation from the filtrate 
with Et2O, 13 is obtained with moderate yields (54%). Single crystals were 
obtained from slow diffusion of hexane into a concentrated solution of 13 in 
CH2Cl2. The structure of the compound was confirmed by X-Ray diffractometry 
(Figure 18). This measurement was carried out by Annalisa Guerri of the 
Crystallographic centre of University of Florence. The Gold(I) atom has the 
usual linear coordination being the angle Cl(1)-Au(1)-C(1) 177.3(2)° and the 
distances Au(1)-Cl(1) and Au(1)-C(1) 1.995(8) and 2.305(2) respectively. 
These bond distances and angles are in agreement with other similar gold 
compounds found with a search in the CSD (v. 5.37 February 2016).101,183,190 
In compound 13, the planes containing the anthracene moiety and the 
benzimidazole one are almost perpendicular to each other (92.2(2)°). 
In the asymmetric unit, π-stacking interactions occur between the aromatic 
moieties of different molecules reported by the symmetry operations: -x+1; y-
1/2, -z+1/2+1 and -x+1; y+1/2, -z+1/2+1. The interactions involve mainly the 
five membered ring of the benzimidazole and the anthracene residues belonging 
to these molecules, the distances between the centroids are 3.94 and 4.45 Å 
respectively. Crystallographic data of the compound are summarized in Table 3 
and 4. 
The compound was furtherly characterized in the solid state by FT-IR and in 
solution through 1H and 13C{1H} NMR in CDCl3. 
In 1H NMR spectrum, the absence of the acidic proton at high chemical shifts 
is a diagnostic feature. The signal of the methylene bound to the anthracenyl 
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moiety is significatively deshielded (δ = 6.76 ppm) in comparison to the same 
signal in 12 (δ = 6.36 ppm). On the contrary, in 13C{1H} NMR the carbenic 
carbon experiences an upfield shift of about 11 ppm in comparison to the 
silver(I) precursor and resonates at δ = 179.9 ppm. This trend is consistent with 
other reports.119,188 The chemical shift of the carbenic carbon of 13 lays in the 
range usually reported for Gold(I)-NHC monocarbenes.180,183,191 
FT-IR spectrum of the complex showed the characteristic stretching of the C-C 
triple bond at ν = 2183 cm-1, slightly lower than the stretching of 11 (ν = 2190 
cm-1). 
 
 
 
Scheme 12. Reaction Synthesis scheme of 13. 
 
Figure 18. Crystallographic structure of 13. 
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 13 
Empirical formula C28H26AuClN2Si 
Formula weight 651.01 
Temperature (K) 100 
Wavelength (Å) 1.54184 
Crystal system, space group Monoclinic, P 21/c 
Unit cell dimensions (Å, °) a = 14.6794(2) 
b = 9.6939(2)            α = 100.936(2) 
c = 19.2852(4) 
Volume (Å3) 2694.46(9) 
Z, Dc  (mg/cm3) 4, 1,605 
 (mm-1) 11.726 
F(000) 1272 
Crystal size (mm) 0.2x0.1x0.1 
 range (°) 4.671 to 72.191 
Reflections collected / unique 15191/5226 
Data / restraints / parameters 5226/ 0 / 301 
Goodness-of-fit on F2 1.086 
Final R indices [I>2(I)] R1 = 0.0447, wR2 = 0.1033 
R indices (all data) R1 = 0.0644, wR2 = 0.1147 
 
Table 3. Crystallographic data for compound 13. 
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 13 
Au(1)C(1) 1.995(8) 
Au(1)Cl(1) 2.305(2) 
C(1)N(1) 1.364(9) 
C(1)N(2) 1.336(9) 
C(24)C(25) 1.2(1) 
C(25)Si(1) 1.857(9) 
Si(1)C(27) 1.9(1) 
Si(1)C(28) 1.8(1) 
Si(1)C(29) 1.8(1) 
C(1)Au(1)Cl(1) 177.3(2) 
N(1)C(1)N(2) 106.7(6) 
C(23)C(24)C(25) 179.5(9) 
C(24)C(25)Si(1) 177.5(8) 
C(25)Si(1)C(26) 105.3(5) 
C(25)Si(1)C(27) 109.0(5) 
C(25)Si(1)C(28) 106.2(5) 
 
Table 4. Bond distances (Å) and angles (°) for compound 13. 
 
3.2.10 Additional attempt to synthetize 1-(9-anthracenylmethyl)3-(1-
trimethylsilyl-3-propynil)-bnzimidazol-2-ylidene Gold chloride (13)  
Preparation of 13 was also attempted with the same reaction already mentioned 
in the discussion on the failed attempt to prepare 9.105 It described the synthesis 
of the Gold(I) carbene through in situ deprotonation of the imidazolium salt 
with an excess of K2CO3 in presence of AuCl(SMe2) (Scheme 13).
 After 
filtration on Celite to separate the KBr formed and the excess of K2CO3, a solid 
was obtained from the filtrate by precipitation with hexane and separated by 
filtration. 1H NMR spectrum showed that the solid contained three set of signals 
two of which had the characteristic signals of the methylene groups of the 
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propinyl and of the anthracenyl moiety (δ = 6.73; 6.71; 5.39; 5.31 ppm) It could 
be hypothesized that the neutral monocarbene and the cationic biscarbene both 
were formed. Et2O was added to the solid, not all the solid dissolved. The 
residue and the solution were separated by filtration. While 1H NMR of this 
solid still revealed the presence of three set of signals, 1H NMR of the solid 
obtained by removing Et2O under reduced pressure from the filtrate showed that 
only two species were present. They were the two compounds mentioned above 
suspected to be the two carbenic complexes.  
 
Scheme 13. Scheme of the attempt to prepare 13 from the imidazolium salt.  
 
3.3 Solution studies 
Stability of compounds 1, 5, 13 in DMSO and in physiologically relevant 
conditions has been investigated by UV-Vis spectrophotometry. 
The solution chemistry of gold carbenes 2 and 3 had already been explored.160 
Notably, the compounds were found to be stable and soluble in phosphate buffer 
50 mM at pH= 7.4 over 24 h, with full retention of their structure. Moreover, in 
the same solution conditions they did not elicit any reduction of the Gold(I) 
centre if treated with large molar excess (up to 100:1) of sodium ascorbate and 
glutathione. 
The compounds under study were first dissolved in DMSO and spectra were 
recorded over 24 h (Figure 19). Notably, all the compounds are soluble and 
stable within this medium.  
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The compounds show transitions between 245 and 400 nm.  
Compound 1 has a broad absorption at 268 nm which can be attributed to two 
contribution: thio-β-glucose-tetracethate intra-ligand transition (IL) and to the 
Gold(I)-NHC cromophore. The latter transition can be straightforwardly 
assigned to a metal-to-ligand charge transfer (MLCT) band. Indeed, the 
imidazolium salt does not have any transitions at these frequencies and Gold(I) 
has a d10 configuration, thus LMCT and LF transitions are absent.192,193 
Similiarly, compound 5 shows broad absorptions with maximums at 270 and 
273 nm that can be ascribed to IL and MLCT transitions. Compound 13 has 
absorptions at λ > 300 nm characteristic of the anthracenyl moiety. Also in this 
case, the other bands can be attributed to IL and MLCT transitions. 
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Figure 19. Absorbance spectra of 1 10-4M (a), 5 10-4M (b) and 13 5·10-5M in DMSO, 
recorded over 24 h at 25°C. 
 
a) 
c) 
b) 
 
 
65 
 
Concentrated solution of 1, 5 and 13 (10-2 M) in DMSO were furtherly diluted 
in a mixture of DMSO and water or phosphate buffer (PB) 50 mM at pH = 7.4 
to a concentration ranging from 5·10-5 M to 1·10-4M. Spectra were recorded 
over 24 h at 25°C (Figure 20, 21, 22).  
A slight decrease in the intensity of absorption occurs over time in the spectral 
profile of 1 and 5, with a simultaneous separation in two peaks in the spectrum 
of 1 (λ = 248 nm and λ = 262 nm).These features could be related to the 
occurrence of a partial hydrolysis process of the ancillary ligand. Analogously 
the same phaenomenon could explain relevant changes in the spectral profile of 
13. 
 
 
Figure 20. Spectra of 5 10-4 M in H2O with 60 % DMSO recorded for 24 h at 25°C, spectral 
profiles at 0, 6, 12, 18, 24 h. 
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Figure 21. Spectra of 1 10-4 M in PB with 20% DMSO recorded for 24 h at 25°C, spectral 
profiles at 0, 6, 12, 18, 24 h. 
 
 
Figure 22. Spectra of 1 5·10-5 M in PB with 5% DMSO recorded for 24 h at 25°C, spectral 
profiles every 3 h. 
 
The stability toward biologically relevant reducing agents such as L-sodium 
ascorbate (Asc) and glutathione (GSH) was investigated. The reducing agent 
was added to freshly prepared 10-4 M or 5·10-5 M solutions of the compounds 
in molar excess up to 100:1.  
Notably, no reduction was observed in any case: the formation of colloidal 
Au(0), usually revealed by a broad absorption between 500-600 nm194 did not 
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occur. However, significant changes in the spectral profile of 5 could be 
ascribed to the formation of Gold(I) thiolates in presence of an excess of 
glutathione (Figure 23).  
 
 
Figure 23. Spectral profiles of the reaction between 5 10-4M and GSH (GSH/ 5 10:1 molar 
ratio) in H2O with 60% DMSO at 25°C, monitored over 90 min every 5 min. The red line 
shows the spectral profile of 5 before adding GSH. 
 
3.4 Interactions with CT-DNA 
 
3.4.1 Interaction between 13 and CT-DNA 
Spectrophotometric characterization of 13 in aqueous environment was carried 
out. UV-Vis absorption spectra of 13 5.0·10-5 M in PB with 5% DMSO recorded 
every 5 min for 2 h at 25°C showed that the absorption band at λ > 350 nm, 
characteristic of the anthracenyl moiety, is signal stable over the time (Figure 
24). A slight decrease in the absorption band between 235 and 335 nm could be 
ascribed to a partial hydrolysis of the chloride ancillary ligand. 
A concentration up to 14 molar excess of CT-DNA was added to the solution 
and absorption spectra were collected (Figure 25). The absence of relevant 
changes in the spectral interval of interest (λ > 350 nm) prevented us from 
further studying the system with spectrophotometric techniques.  
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Figure 24. Absorption spectra of 13 5.0·10-5 M in PB (50 mM, pH = 7.4) with 5% DMSO, 
recorded every 5 min for 2 h at 25°C. 
 
 
 
Figure 25. Absorption spectra of 13 5.0·10-5 M in PB (50 mM, pH = 7.4) with 5% DMSO 
before and after adding a molar excess of CT-DNA up to 14:1. Spectra recorded every 5 min 
at 25°C. 
 
Therefore, we decided to proceed with spectrofluorimetric measurements. First 
of all emission and excitation spectra at different wavelengths of 13 (2.5·10-5 M 
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in PB with 5% DMSO) were recorded at 25°C. For the measurement, λex = 255 
nm; λem = 480 nm; slit = 5 nm were chosen as the best parameters. Moreover, 
we made sure that the signal was stable over time. Fluorescence emission 
spectra were recorded every 5 min interval for 2 h. No change of the emission 
properties was observed, indicating stability of the system under these 
conditions. Fluorescence spectra (λexc = 255 nm) at varying concentrations were 
recorded to demonstrate the respect of Lambert-Beer Law. Linearity between 
concentrations in 1-5·10-6 M range and fluorescence emission at λem = 395 nm 
was verified. Upon addition to the solution of 13 (2.5·10-5 M in PB with 5% 
DMSO) of a 7-fold molar excess of CT-DNA a relevant decrease of 
fluorescence occurred, revealing some kind of interaction going on (Figure 26). 
These data indicate that, for the here analysed system, fluorescence is more 
sensitive to dye interaction with the substrate. 
 
 
 
Figure 26. Emission spectra (λexc = 255 nm) of 13 2.5·10-5 M in PB (50 mM, pH = 7.4) with 
5% DMSO (blue line) and after adding a 7-fold molar excess of CT-DNA (red line). 
 
Therefore we could proceed with a spectrofluorometric titration to investigate 
the interaction between the compound and CT-DNA. There are several reports 
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of the use of this measurements to investigate nature and thermodynamic 
features of these kind of binding.142,195,196 
In this experiment increasing amounts of a solution of CT-DNA (C°P = 3.40·10
-
4 M in PB) are added to the solution of 13 whose initial concentration is C°D = 
3.02·10-6 M in PB. Emission spectra were recorded at 24.4°C and fluorescence 
values at λem = 395 nm were collected. A decrease of fluorescence at increasing 
concentrations of CT-DNA was observed (Figure 27). 
 
 
 
Figure 27. Fluorimetric titration of 13 (C°D= 3.02·10
-6 M in PB with 5% DMSO) with CT-
DNA (C°P= 3.40·10
-4 M in PB) at 24.4°C. 
 
Data are elaborated using the method197 described below that allows calculation 
of the equilibrium constant for the binding interaction. The binding process is 
described by the apparent reaction in Equation 2 and the correspondent binding 
equilibrium constant in Equation 3, where P is the polynucleotide (DNA) and 
D is the dye 13  
                       P + D ⇄ PD                                                                   (2) 
                        𝐾 =
[𝑃𝐷]
[𝑃][𝐷]
                                                                     (3) 
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Equations 4, 5 and 6 can be applied. considering the conservation of the mass 
and that fluorescence can be generally wrote as F= φ[C] that describes its 
proportionality to concentration.  
𝐶𝐷 = [𝐷] + [𝑃𝐷]                                (4) 
𝐶𝑃 = [𝑃] + [𝑃𝐷]                                 (5) 
𝐹 = 𝜑𝐷𝐶𝐷 + 𝜑𝑃𝐷[𝑃𝐷]                       (6) 
If ΔF= F - φDCD that is the difference of fluorescence between our system and a 
solution that only contains the dye, Equation 6 can be rearranged as Equation 7. 
𝛥𝐹 = 𝛥𝜑[𝑃𝐷]                                         (7) 
To follow the titration, the isotherm of binding is obtained by plotting ΔF/CD 
against CP (Figure 28). 
  
 
 
Figure 28. Binding isotherm of the system 13-DNA at 24.4°C. 
 
Data can be furtherly elaborated: expressing the equilibrium constant only in 
function of [PD] using Equation 4 and 5 and expressing [PD] as ΔF/Δφ 
(Equation 8) Equation 9 can be easily obtained. 
 
[𝑃𝐷] = 𝐾[𝑃][𝐷] = 𝐾(𝐶𝑃 − [𝑃𝐷])(𝐶𝐷 − [𝑃𝐷])               (8) 
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If the term on the left is plotted against CP+CD a line is obtained with intercept 
equal to 1/KΔφ and slope equal to 1/ Δφ. Δφ is the only unknown value to be 
obtained to calculate K. In this model, we suppose that at the end of the titration 
all the dye is bound in the complex (or that emission is only due to the complex 
13-DNA) so that we can write Equations 10 and 11. Therefore, in a first 
approximation Δφ is the amplitude of the isotherm of binding. This Δφ is used 
to obtain a first plot according to Equation 9. A new value of Δφ can be obtained 
from the slope of this line employed for a second plot. This process is iterated 
until convergence of Δφ values.  
 
                [𝑃𝐷] = [𝐶𝐷] =
𝛥𝐹
𝛥𝜑
                                   (10) 
                  𝛥𝜑 =
𝛥𝐹
[𝐶𝐷]
                                                 (11) 
For the interaction between CT-DNA and 13 at 24.4°C a value of K= 4.02·104 
M-1 was obtained. 
Spectrofluorimetric titrations were carried out also at T= 9.9°C and T= 39.8 °C 
using the same procedure. Binding constants obtained are respectively K= 
8.71·104 M-1 and K= 1.80·104 M-1.  
According to the Van’t Hoff equation (Equation 12), The lnK was plotted 
against 1/T, the line obtained has a slope equal to –ΔH/R and an intercept equal 
to ΔS/R (Figure 29). We obtained values of ΔH= -9.27 Kcal/mol and ΔS= -0.01 
Kcal/mol·K for the reaction.  
𝑙𝑛𝐾 = −
𝛥𝐻
𝑅
1
𝑇
+
𝛥𝑆
𝑅
                        (12) 
These thermodynamic values are consistent with intercalation.198  
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Figure 29. Van’t Hoff plot: dependence of lnK from 1/T with T= 9.9, 24.4, 39.8 °C 
 
3.4.2 Interaction between 4 and CT-DNA 
Preliminary spectrophotometric characterization of 4 in aqueous environment 
was carried out. UV-Vis absorption spectra of 4 5.0·10-5 M in PB (50 mM, pH= 
7.4) recorded every 90 s for 2 h at 25°C showed that the compound was not 
stable in this medium (Figure 30). Probably the excess of phosphate ion reacts 
with the cluster with the substitution of a CO ligand, as already observed for 
this compound in presence of nucleophiles.151,154 On the contrary, no changes 
occurred in the absorption spectral profile of 4 5.0·10-5 M in NaCac (2.5 mM, 
pH= 7.0) after 2 h (Figure 31). Therefore, further measurements were carried 
out in this medium 
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Figure 30. Absorption spectra of 4 5.0·10-5 M in PB (50 mM, pH= 7.4) recorded every 90 s 
for 2 h at 25°C. 
 
 
 
Figure 31. Absorption spectra of 4 5.0·10-5 M in NaCac (2.5 mM, pH= 7.0) recorded every 
90 s for 2 h at 25°C. 
 
UV-Vis absorption spectra of a solution of 4 5.0·10-5 M in NaCac with a 7-fold 
molar excess of CT-DNA didn’t reveal any change straightforwardly 
attributable to an interaction between the two species and useful for a 
spectrophotometric titration (Figure 32). Thus, since no fluorophore is present 
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on the cluster that could allow spectrofluorimetric measurements, we decided 
to investigate the system 4-DNA by means of viscosimetric titrations. 
 
 
 
Figure 32. Absorption spectra of 4 5.0·10-5 M in NaCac (2.5 mM, pH= 7.0) at 25°C (blue 
profile) and absorption spectra of the same solution with addition of CT-DNA 3.74·10-4 M.  
 
Measures of viscosity can be employed to study the binding between small 
molecules and polynucleotides.147,199 This interaction can modify the chain 
length and viscosity is proportional to the third power of chain-length of 
polynucleotides in the rigid rod approximation.200,201 
In this experiment, the polymer concentration was kept constant (CP= 2.6·10
-4 
M) and CD was varied in the CD/CP= 0.05-0.74 range. The relative viscosity was 
calculated as (Equation 13): 
𝜼
𝜼𝟎
=
(𝒕−𝒕𝒔𝒐𝒍𝒗)
(𝒕𝑫𝑵𝑨−𝒕𝒔𝒐𝒍𝒗)
                                       (13) 
where t is the time of outflow of the sample (4-DNA mixture), tsolv and tDNA are 
respectively the time of outflow of the solvent alone (NaCac 2.5 mM) and of 
the DNA+solvent. Since 4 was added from a stock solution 4.63 10-4 M in 
DMSO, when measuring tsolv and tDNA we add to the solvent or to the DNA 
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suitable amounts of a mixture of NaCac 2.5 mM and DMSO (CDMSO= 5.08 10
-4 
M) to equal the amount of DMSO added in the samples 4-DNA. This way we 
could take into account the (although small) variation of viscosity due to the 
increasing concentration of DMSO. Measures were collected at T= 40°C. The 
plot in Figure 33 shows the dependence of (η/η0)1/3 on (CD/CP). Error bars were 
empirically approximated as │(η/η0)1/3max/min−(η/η0)1/3mean│/2. Considering 
these error bars, no significant change in the viscosity of CT-DNA upon 
addition of 4 occurred.  
To conclude, no DNA interaction with CG7 was enlightened neither with 
spectrophotometric techniques nor with viscosimetry. 
 
 
 
Figure 33. Plot of relative viscosity against CD/CP ratio for the DNA/4 system. CP = 2.6·10
-4 
M in NaCac 2.5 10-3 M, pH = 7.0; T = 40.0°C. 
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4. Conclusions  
The present work involved the investigation of the possible anticancer 
properties of a series of organometallic compounds. It consisted of three main 
parts: first the biological activity of a small panel of organometallic complexes 
including the investigation of their antiproliferative effects against different 
human tumour cell lines and of their toxicity toward kidney slices was 
evaluated; secondly two novel Gold(I)-NHC compounds with possible 
biological activity were prepared and finally the study of the interaction with 
CT-DNA of two representative compounds was carried out. 
As for the inhibition study of tumour cells growth, the majority of the tested 
compounds showed high cytotoxicity towards human tumour cell lines. These 
antiproliferative effects were not related to p53 expression in HCT 116 cell 
lines, differently from the case of CDDP, making these compounds promising 
anticancer agents on CDDP resistant cell lines. 
In spite of the good results in vitro, the most active compounds (1, 2, 3) turned 
out to have an acute toxicity on kidney tissue, result which could create issues 
concerning the side effects of a drug.  
Following the results of biological activity studies a new compound with 
potential theranostic properties was designed. Synthesis of compound 13 has 
been carried out with moderate yields. This compound is a novel Gold(I)-NHC 
compound bearing a benzimidazole that was N-disubstituted with a fluorophore 
(a methyl-anthracenyl group), and an alkinyl functional group (a propynyl with 
a terminal trimethylsilyl moiety) for a future bioconjugation. Functionalization 
of the benzimidazole to obtain the corresponding benzimidazolium salt turned 
out to be rather facile. Analogously, the Gold(I)-NHC synthetic pathway that 
involved deprotonation of the benzimidazolium salt with Ag2O to bear the 
Ag(I)-NHC complex and subsequent transmetalation with AuCl(SMe2) was 
convenient and required mild conditions. The chemical structure of 13 was 
confirmed with X-Ray diffractometry. Notably, spectrofluorimetric 
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measurements showed that the compound was able to intercalate in CT-DNA. 
Evaluation of the in vitro antiproliferative activity of this complex and of the 
eventual bioconjugated derivative would be of interest as well as in vitro 
localization with fluorescence imaging.  
Furthermore, a novel analogue of Auranofin, 1, was obtained from compound 
2 already found to have highly cytotoxic toward various cancer cell lines, by 
substituting the chloride ancillary ligand of 2 with the same thiosugar ligand of 
Auranofin. The compound was obtained in high yields and its biological activity 
toward cancer cell lines and kidney tissues has been evaluated with the series of 
compounds mentioned above. Complex 1 showed promising in vitro 
antiproliferative effects but it was found to have acute toxicity on kidney tissue. 
It would be interesting to prepare a derivative with a different NHC ligand to 
try to obtain a less toxic compound. 
UV-Vis spectrophotometry showed that the compounds under study are 
sufficiently stable for the use in physiological conditions. Their stability toward 
reduction will also be confirmed through cyclic voltammetry measurements.  
Preliminary mechanistic studies on compound 4 (the trinuclear Platinum 
cluster) involved the investigation of interaction with CT-DNA. Viscosimetric 
and spectrophotometric measurements on 4 didn’t reveal any interaction with 
CT-DNA. The absence of any binding interaction could be also confirmed with 
ESI-MS, but, for now, we could hypothesize that DNA may not be the 
biomolecular target primarily responsible for the in vitro biological activity of 
the platinum cluster. 
Further researches could elucidate the cellular uptake of the compounds under 
study and investigate whether Gold(I)-NHC complexes accumulate in 
mitochondria as the majority of similar Gold(I) compounds reported in 
literature.72 ICP-MS could be a useful technique for similar studies. Finally, it 
could be interesting to carry out apoptosis studies and investigate the interaction 
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with some target proteins (such as TrxR) as to have mechanistic insights on the 
biological activity of this panel of compounds.  
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5 Experimental part  
 
5.1 Synthesis  
Unless stated otherwise the reactions were performed under inert atmosphere of 
nitrogen. Vacuum (10-2 mmHg) was obtained with a mechanical oil pump. 
5.1.1 Materials 
Solvents and reagents were purchased from Sigma Aldrich. 
DMF was kept on molecular sieves. 
Et2O and hexane were used without previous treatment. 
CH2Cl2 was refluxed and distilled over P2O5. 
K2CO3 was dried in the oven at 120°C for a night and kept in the dryer before 
use.  
4-Bromo-butyne was prelevated under inert atmosphere. 
Au(BMIm)Cl (2) was prepared according to procedures previously reported by 
the research group I worked in.160 
AuCl(SMe2) was synthetized according to a procedure reported in literature
202. 
The other reagents were used without any other treatment. 
 
5.1.2 Instruments 
NMR spectra were collected on a Varian Gemini 200 BB instrument (1H, 200 
MHz; 13C, 50.3 MHz) at room temperature; frequencies are referenced to TMS. 
FT-IR spectra were recorded on a Spectrum One Perkin Elmer instrument 
equipped with an UATR unit. 
Data Collection was carried out on an Oxford Diffraction XCaliburPX 
diffrattometer, equipped with a low temperature device (data collection was 
performed at 100 K), a CCD area detector and the Cu Kα radiation (λ = 1.54184 
Å). The program suite CrysAlis (v. 1.171.37.35g)203 was used both to design the 
strategy for the data collection and for the data reduction. The absorption 
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correction was executed through the program SCALE3 ABSPACK 
implemented in the CrysAlis package. 
 
5.1.3 Synthesis of thio-β-D-glucose-tetraacetate-(1-butyl-3-methyl)-
imidazol-2-ylidene-Gold(I) (1) 
37 mg of Au(BMIm)Cl (0.100 mmol) were dissolved in 15 ml of CH2Cl2. 138 
mg of K2CO3 (1.00 mmol) and 36 mg of thio-β-glucose-tetracethate (tgt) (0.100 
mmol) were added to the solution. The suspension was stirred at room 
temperature for 30 min in the dark. The mixture was filtered and the filtrate was 
concentrated to about 2 ml. The product was precipitated with hexane, filtered 
and the solid was washed with hexane to obtain a light brown solid (66 mg, 
0.095 mmol, yield= 95%). 
1H NMR (CDCl3) : δ (ppm) = 6.94 (s, 1H, H4 or H5); 6.93 (s, 1H, H4 or H5); 
5.05- 4.96 (m, 3H, tgt); 4.14- 4.04 (m, 5H, H6, 3H tgt) ; 3.76 (s, 3H, H10); 3.66 
(m, 1H, H5’); 2.01, 1.95, 1.92, 1.89 ( s, 3H, OAc); 1.75 (apparent quintet J = 7.5 
Hz, 2H, H7a-b); 1.26 (apparent sextet J = 7.5 Hz, 2H, H8a-b); 0.87 (t 
2J = 7.5 Hz, 
3H, H9). 
13C{1H} NMR (CDCl3): δ (ppm) = 183.7 (C2); 170.5, 170.1, 169.5, 169.4 
(C=O); 121.7, 120.4 (C4 and C5); 83.0 (C1’); 77.5 (C2’); 75.7 (C5’); 74.4 (C3’); 
69.1 (C4’); 63.0 (C6’); 50.4 (C6); 38.1 (C10); 33.2 (C7); 21.2, 20.8, 20.7 20.6 
(OAc); 19.7 (C8); 13.7 (C9) . 
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IR (solid state): ν (cm-1) = 2962 (w-m); 2916 (w); 2870 (vw); 1744 (m); 1567 
(vw); 1469 (w); 1412(w); 1258 (s); 1220 (m); 1086 (s); 1016 (vs); 911 (w-m); 
865 (w-m); 795 (vs); 734 (w-m); 680 (w-m).  
 
5.1.4 Synthesis of 1-(9-anthracenylmethyl) imidazole (6) 
77 mg of imidazole (1.13 mmol) were dissolved in 1 ml of DMF. 170 mg (1.23 
mmol) of K2CO3 were added and the suspension was stirred for 30 min at room 
temperature. Subsequently, a solution of 256 mg (1.13 mmol) of 9-
(chloromethyl)anthracene in 1 ml of DMF was added dropwise. The suspension 
was stirred at 50°C for 12 h. The reaction was quenched with 5 ml of H2O and 
the mixture extracted with 3×10 ml of CH2Cl2. The combined yellow organic 
phases were washed repeatedly with water and then anhydrificated with 
Na2SO4. A yellow side-product was precipitated on adding Et2O to the filtrate, 
separated off and analysed with 1H NMR. 1H NMR (CDCl3): δ (ppm) = 11.82 
(s); 8.59 (s); 8.53 (s); 8.33 (d); 8.18- 8.00 (m); 8.02 (d); 7.67- 7.49 (m); 6.62 (s); 
6.40 (s); 6.31 (s). The solvent was removed from the filtrate under reduced 
pressure. The light orange solid obtained was washed with hexane to bear the 
product 6 with a 45% yield (131 mg, 0.509 mmol). 
1H NMR (CDCl3): δ (ppm) = 8.57 (s, 1H, anthracenyl); 8.18 (d, 2J = 8.6 Hz, 2H, 
anthracenyl); 8.08 (d, 2J = 8.6 Hz, 2H, anthracenyl); 7.62- 7.47 (m, 4H, 
anthracenyl and 1H, NCHN); 6.99 (s, 1H, NCHCHN); 6.86 (s, 1H, NCHCHN); 
6.07 (s, 2H, CH2-anthracenyl). 
13C{1H} NMR, (CDCl3): δ (ppm) = 136.8 (NCHN); 131.5 (Cquat anthracenyl); 
130.9 (Cquat anthracenyl); 129.7 (CH anthracenyl); 129.6 (CH anthracenyl); 
129.0 (CH imidazole); 127.5 (CH anthracenyl); 125.4 (CH anthracenyl); 124.6 
(Cquat anthracenyl); 123.0 (CH anthracenyl); 119.1 (CH imidazole); 43.4 (CH2-
anthracenyl). 
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5.1.5 Synthesis of 1-(9-anthracenylmethyl)3-(4-butynil)imidazolium 
bromide (7) 
118 mg of 6 (0.483 mmol) were dissolved in 15 ml of toluene, then 68 µl of 4-
bromo-butyne (d= 1.417 g/ml, 0.725 mmol) were added to the solution. The 
reaction mixture was allowed to reflux for a week, over time a white solid 
precipitated. The solid was recovered by filtration and washed with toluene and 
hexane to give 7 with a yield of 20% (0.0966 mmol, 38 mg). 
1H NMR (CDCl3): δ (ppm) = 10.96 (s, 1H, NCHN); 8.62 (s, 1H, anthracenyl); 
8.35 (d, 2J = 8.7 Hz, 2H, anthracenyl); 8.09 (d, 2J =8.4 Hz, 2H, anthracenyl); 
7.72-7.51 ( m, 4H, anthracenyl); 7.30 (s, 1H, NCHCHN); 6.81 (s, 1H, 
NCHCHN); 6.62 (s, 2H, CH2-anthracenyl); 4.54 (t, 
2J = 6.0 Hz, 2H, N-
CH2CH2CCH); 2.89 (m, 2H, N-CH2CH2CCH); 1.98 (t, 
3J = 2.3 Hz, 1H, N-
CH2CH2CCH). 
13C{1H} NMR (CDCl3): δ (ppm) = 137.7 (NCHN); 131.2, 130.8 , 130.7, 129.5, 
128.4, 125.5 (CH anthracenyl), 122.8 (CH imidazole); 121.9, 121.3 (Cquat 
anthracenyl), 120.7 (CH imidazole); 78.7 (N-CH2CH2CCH); 72.8 (N-
CH2CH2CCH); 48.6 (N-CH2CH2CCH); 46.0 (CH2-anthracenyl); 20.8 (N-
CH2CH2CCH).  
 
5.1.6 Attempt to synthetize 1-(9-anthracenylmethyl)3-(4-butynil)-imidazol-
2-ylidene Silver Bromide (8) 
38 mg (0.0971 mmol) of 7 were dissolved in a mixture of CH2Cl2/MeOH (3:1), 
15 mg (0.0647 mmol) of Ag2O were added and the mixture was stirred at room 
temperature for a day. The mixture was filtered over Celite and the solvent was 
removed under reduced pressure to bear a light brown solid. 1H NMR spectra 
showed the formation of a mixture of products. 
1H NMR (CDCl3): δ (ppm) = 11.26 (s); 8.64 (s); 8.61(s); 8.58 (s); 8.53 (s); 8.35 
(d); 8.26-8.19 (m); 8.13- 8.04 (m); 7.84 (s); 7.69 (s); 7.74- 7.48 (m); 7.25 (s); 
7.00 (s, br); 6.93 ( d, J = 1.9 Hz); 6.87 (br); 6.75 (s, br); 6.62 8s); 6.46 (d, J= 1.9 
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Hz); 6.29 (s); 6.13 (d J = 2.9 Hz); 6.10 (s); 5.79 (s); 5.76 (d, J = 2.9 Hz); 4.65 
(m); 4.55 (t, J = 6.4 Hz); 4.3 ( t, J = 6.4 Hz); 3.84 ( t, J = 6.8 Hz); 3.42 (s); 2.88 
(t, J = 5.01 Hz); 2.73 (m); 2.65- 2.56 (m); 2.35 (s); 2.22- 2.18 (m); 2.09 ( t, J = 
2.6 Hz); 1.92 ( t, J = 2.6 Hz); 1.90 (m). 
 
5.1.7 Attempt to synthetize 1-(9-anthracenylmethyl)3-(4-butynil)-imidazol-
2-ylidene Gold chloride (9) 
20 mg (0.0511 mmol) of 7 were dissolved in 10 ml of CH2Cl2, 15 mg (0.0511 
mmol) of AuCl(SMe2) were added and the mixture was stirred at room 
temperature for 15 min. Subsequently, 120 mg (0.868 mmol) of K2CO3 were 
suspended and the mixture was reacted for 6 h. The suspension was filtered over 
Celite. The filtrate was concentrated and precipitated with Et2O. The white solid 
was filtered and washed with Et2O. 
1H NMR spectra showed three set of signals 
attributable to compound 7 and to other products in comparable amounts, one 
of which could be 9. However, it was not possible to separate these species. 
1H NMR (CDCl3): δ (ppm) = 10.16 (s); 9.68 (s); 8.66 (s); 8.62 (s); 8.57 (s); 8.42-
8.31 (m); 8.10 (pseudo t, J2 = 7.5 Hz); 7.85-7.52 (m); 7.38 (s); 7.04 (s); 6.95 (s); 
6.90 (s); 6.86(s); 6.64 (s); 6.55 (s); 6.42 (s); 6.36 (s); 4.56 (t, J2 = 6.1 Hz); 4.42 
(t, J2 = 6.5 Hz); 3.19- 3.03 (m); 2.89 (m); 2.12 (m); 2.06 (m); 1.93 (t, J = 2.3 
Hz). 
 
5.1.8 Synthesis of 1-(9-anthracenylmethyl)benzimidazole (10)  
180 mg of benzimidazole (1.52 mmol) were dissolved in 1.5 ml of DMF. After 
adding 230 mg (1.66 mmol) of K2CO3 the suspension was stirred at room 
temperature for 30 min. Subsequently, a solution of 376 mg of 9-
(chloromethyl)anthracene (1.66 mmol) in 3.5 ml of DMF was added dropwise. 
The orange suspension obtained was heated to 50°C and stirred for 18 h. To 
quench the reaction, 12 ml of H2O were added causing the precipitation of a 
yellow solid. The suspension was extracted with 3×20 ml of CH2Cl2 . The 
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combined organic phases were washed with water repeatedly and dried over 
Na2SO4. The solution was concentrated under reduced pressure. The product 
was obtained as an orange microcrystalline solid after precipitation with hexane 
at low temperature (-20°C). (384 mg, 1.25 mmol, yield = 82%). 
1H NMR (DMSO- d6): δ (ppm) = 8.75 (s, 1H, anthracenyl); 8.43 (d, 2J = 8.3 Hz, 
2H, anthracenyl); 8.17 (d, 2J = 8.3 Hz, 2H, anthracenyl); 7.78 (s, 1H, NCHN); 
7.64-7.47 (m, 4H anthracenyl and 2H benzimidazole); 7.17 (m, 2H, 
benzimidazole); 6.45 (s, 2H, CH2- anthracenyl). 
13C{1H} NMR (DMSO- d6): δ (ppm) = 143.3 (NCHN); 134.1 (Cquat ); 131.2 (CH 
benzimidazole anthracenyl); 130.7 (Cquat or CH); 129.6 (CH anthracenyl); 129.3 
(Cquat or CH); 127.5 (CH, anthracenyl); 125.7 (CH anthracenyl); 123.8 (CH 
anthracenyl); 122.8 (CH anthracenyl or benzimidazole); 119.6 (CH 
benzimidazole); 111.0 (CH benzimidazole); 41.0 (CH2- anthracenyl). 
 
5.1.9 Synthesis of 1-(9-anthracenylmethyl)3-(1-trimethylsilyl-3-propynil) 
benzimidazolium bromide (11) 
239 mg of 10 (0.776 mmol) were dissolved in 1.5 ml of DMF. 152 µL of 3-
bromo-1-trymethylsilylpropyne (d = 1.17 g/ml , 0.929 mmol) were added to the 
solution. The reaction mixture was stirred at 40°C for 3 days. Precipitation with 
Et2O gave a white solid (0.574 mmol, 287 mg, yield= 74%). 
1H NMR (CDCl3): δ (ppm) = 11.20 (s, 1H, NCHN); 8.61 (s, 1H, anthracenyl); 
8.47 (d, 2J = 8.3 Hz, 2H, anthracenyl); 8.09 (d, 2J= 8.3 Hz, 2H, anthracenyl); 
7.83 (d, 2J = 8.4 Hz, 1H, benzimidazole); 7.71 (m, 2H, benzimidazole); 7.54 (t, 
2J=8.3 Hz, 2H, anthracenyl); 7.31 (t 2J= 8.3, 2H, anthracenyl); 7.23 (d 2J= 8.4 
Hz , 1H, benzimidazole); 6.82 (s, 2H, CH2-anthracenyl); 5.52 (s, 2H, N-
CH2CCSiMe3); 0.08 (s, 9H, SiMe3). 
13C{1H} NMR (CDCl3): δ (ppm)= 142.2 (NCHN); 131.6 (Cquat); 131.3 (CH 
anthracenyl or benzimidazole), 131.2(Cquat), 131.1, 131.0 (CH anthracenyl or 
benzimidazole); 129.8 (CH anthracenyl); 128.6 (CH anthracenyl); 127.4; 127.0; 
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125.6, 122.9 (CH anthracenyl); 121.1 (Cquat); 114.3, 114.0 (Cquat); 95.3, 94.5 
(CC-SiMe3 and CC-SiMe3); 45.6 (CH2-anthracenyl); 39.1 (N-CH2CCSiMe3); -
0.5 (SiMe3). 
IR (solid state): ν (cm-1)= 3132 (w); 3037 (w); 2959 (w); 2897 (w); 2857 (w); 
2190 (w); 1613 (w); 1556 (m); 1488 (w-m); 1461 (w-m); 1451 (w-m); 1422 
(w); 1345 (w-m); 1380 (w-m), 1250 (m); 1189(m); 1137 (w); 1032(m); 1008 
(m), 943 (vw); 844 (vs); 796 (w); 759 (s); 748 (s); 730 (m, sh); 705 (s); 684 (m). 
 
 5.1.10 Synthesis of 1-(9-anthracenylmethyl)3-(1-trimethylsilyl-3-
propynil)-benzimidazol-2-ylidene Silver bromide (12) 
75 mg of 11 (0.150 mmol) were dissolved in 3 ml of CH2Cl2. 23 mg (0.100 
mmol) of Ag2O were added and the reaction vessel was kept in absence of light. 
The suspension was stirred at room temperature for 2 days, after which a 
significant lowering of the quantity of Ag2O was noticed. The suspension was 
filtered through Celite to eliminate the excess of Ag2O. The solvent was 
removed under reduced pressure to obtain a yellow solid (33 mg, 0.0540 mmol, 
yield= 36%).  
1H NMR (CDCl3): δ (ppm)= 8.51 (s, 1H, anthracenyl); 8.19 (d, 2J= 8.6 Hz, 2H, 
anthracenyl); 8.02 (d, 2J= 8.4 Hz, 2H, anthracenyl); 7.63-7.41 (m, 4H 
anthracenyl, 1H, benzimidazole); 7.30 (t 2J=7.6 Hz, 1H, benzimidazole); 7.12 
(t 2J=7.6 Hz, 1H, benzimidazole); 7.02 (d 2J=7.6 Hz , 1H benzimidazole); 6.36 
(s, 2H, CH2-anthracenyl); 5.19 (s, 2H, N-CH2CCSiMe3); 0.13 (s, 9H, SiMe3). 
13C{1H} NMR, (CDCl3): δ (ppm)= 191.5 (NCN ); 134.4 (Cquat); 133.5 (Cquat); 
131.4 (CH anthracenyl or benzimidazole); 131.1 (CH anthracenyl or 
benzimidazole); 130.3 (CH anthracenyl or benzimidazole); 129.9 (CH 
anthracenyl); 128.5 (Cquat); 127.7 (CH anthracenyl); 125.3 (CH anthracenyl); 
124.3, 124.2 (CH anthracenyl or benzimidazole); 123.1 (CH anthracenyl); 
112.2, 112.1(Cquat); 97.4, 93.1 (CC-SiMe3 and CC-SiMe3); 46.7, 41.2 (CH2- 
anthracenyl and N-CH2CCSiMe3); -0.2 (SiMe3).  
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5.1.11 Synthesis of 1-(9-anthracenylmethyl)3-(1-trimethylsilyl-3-propynil)-
benzimidazol-2-ylidene Gold Chloride (13) 
33 mg of 7 (0.0540 mmol) were dissolved in 3,5 ml of CH2Cl2 and 16 mg of 
AuCl(SMe2) (0.0540 mmol) were added. The mixture was stirred at room 
temperature for 4 h , in absence of light. The precipitation of a white solid 
(AgBr) was observed immediately. The suspension was filtered over Celite. The 
yellow filtrate was concentrated under reduced pressure and the product was 
precipitated with Et2O at low temperature (-20°C). A pale yellow solid was 
obtained with 54% yield (19 mg, 0.0292 mmol). Single yellow crystals suitable 
for X-rays diffractometry were obtained from slow diffusion of hexane into a 
concentrated CH2Cl2 solution of 13. The structure was solved by the direct 
methods implemented in the Sir97 program204 and then refined against F2 by 
full-matrix least-squares techniques using SHELXL-2013205 with anisotropic 
displacement parameters for all non-hydrogen atoms. All hydrogen atoms in 13 
were introduced in calculated positions and refined according to a riding model 
with isotropic thermal parameters. All calculations were performed by using the 
program PARST206 and molecular plots were produced with ORTEP3207, both 
implemented in the Crystal Structure crystallographic software package 
WINGX.208 
1H NMR (CDCl3): δ (ppm) = 8.60 (s, 1H, anthracenyl); 8.46 (d, 2J =8.3 Hz, 2H, 
anthracenyl); 8.08 (d, 2J =8.3 Hz, 2H, anthracenyl); 7.63-7.48 (m, 4H, 
anthracenyl, 1H benzimidazole); 7.19 (d, 2J =8.0 Hz, 1H, benzimidazole); 6.88 
( t, 2J =8.0 Hz, 1H, benzimidazole); 6.76 (s, 2H, CH2-anthracenyl); 6.53 (d, 
2J 
=8.8 Hz, 1H, benzimidazole); 5.40 (s, 2H, N-CH2CCSiMe3); 0.15 (s, 9H, 
SiMe3). 
13C{1H} NMR (CDCl3): δ (ppm) = 179.9 (NCN); 133.5 (Cquat); 133.0 (Cquat); 
131.4 (CH benzimidazole or anthracenyl); 130.3 (CH benzimidazole or 
anthracenyl); 129.9 (CH anthracenyl); 128.7 (Cquat); 127.7 (CH anthracenyl); 
125.4 (CH anthracenyl); 124.7, 124.4 (CH anthracenyl or benzimidazole); 
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123.4 (CH anthracenyl); 122.9 (Cquat); 112.9, 112.2 (Cquat); 96.6, 93.3 (CC-
SiMe3 and CC-SiMe3); 48.0, 40.5 (CH2- anthracenyl and N-CH2CCSiMe3); -0.2 
(SiMe3). 
IR (solid state): ν (cm-1) = 3053 (w), 2962 (w); 2896 (w);2184(w) 1622 (w); 
1524 (w); 1478 (w); 1429 (w-m); 1401 (m-s); 1339 (m); 1329 (m); 1250 (m); 
1197 (m); 1197 (w); 1154 (w); 1100 (w, br); 1054 (w-m); 1029 (m); 1014 (w-
m); 892 (w); 842 (s); 798 (m); 784 (w-m); 753 (w-m, sh); 735 (vs); 718 (m-s). 
 
5.1.12 Additional attempt to synthetize 1-(9-anthracenylmethyl)3-(1-
trimethylsilyl-3-propynil)-bnzimidazol-2-ylidene Gold Chloride (13)  
26 mg (0.0520 mmol) of 11 and 15 mg (0.0520 mmol) of AuCl(SMe2) were 
dissolved in 1.5 ml of CH2Cl2 and stirred at room temperature for 15 min. The 
reaction vessel was protected from light. 82 mg (0.593 mmol) of K2CO3 were 
suspended. After 4 h stirring at room temperature the reaction mixture was 
filtered over Celite. The solution was concentrated and a yellow solid was 
precipitated with hexane: it was analyzed with 1H NMR and showed to contain 
three species. Et2O was added to the solid, the precipitate and the filtrate were 
separated by filtration and analysed with 1H NMR. The solid still was composed 
by three species, while the ethereous solution dryed under reduced pressure 
contained two set of signals one of which should be 13. However the product 
could not be isolated.  
1H NMR of the solid obtained from ethereous solution (CDCl3): δ (ppm) = 8.72 
(s, 1H); 8.61 (s, 1H); 8.47 (pseudo d 2J = 8.0 Hz, 2H); 8.36 ( pseudo d 2J = 8.5 
Hz, 2H); 8.17-8.04 (m, 5H); 7.88-7.50 ( m, 13H); 6.98- 6.84 (m, 2H); 6.77 (s, 
2H); 6.69 (s, 2H); 6.55 (t 2J = 8.8 Hz,1H); 5.39 (s, 2H); 5.24 (s, 2H); 0.16 (s, 
6H); 0.03 (s, 9H). 
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5.2 Solution studies 
 
5.2.1 Instruments 
UV- Vis spectra were recorded on an Agilent Cary 60 spectrophotometer. 
 
5.2.2 Materials and General procedure 
Phosphate buffer was prepared dissolving a suitable amount of sodium 
dihydrogen-phosphate in MilliQ water (bidistilled ultrapure water) and by 
adjusting the pH with NaOH or HClO4. 
Stock solutions of the compounds tested (10-2 M) were prepared by dissolving 
a known amount of the solids in DMSO. 
UV-Vis absorption spectra in DMSO and in acqueous solutions were recorded 
at 25°C over 24 h.  
Sodium L-ascorbate was purchased from Fluka and GSH from Alfa Aesar. 
Stock solutions (10-1 M) of Sodium L- ascorbate and GSH were prepared by 
dissolving a known quantity of the solids in MilliQ water. Absorption spectra 
of each compound with a molar excess (10 fold, 50 fold, 100 fold) of sodium 
L-ascorbate or GSH were recorded at 25°C. 
 
5.3 Biological activity studies 
 
5.3.1 Cell lines 
The human colorectal carcinoma HCT 116 p53 null and wt p53 variants (kindly 
provided by Dr. Götz Hartleben, University of Groningen), the human breast 
adenocarcinoma MCF-7 (Leibniz-Institut DSMZ - Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH), and human malignant melanoma 
A375 (kindly provided by Prof. Sylvestre Bonnet, Leiden University) were 
cultured in DMEM (Dulbecco’s Modified Eagle Medium) containing Glutamax 
supplemented with 10% FBS and 1% penicillin/streptomycin (all from 
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Invitrogen), at 37 °C in an incubator (Thermo Fisher Scientific, US) with 
humidified atmosphere of 95% of air and 5% CO2.  
 
5.3.2 In vitro cytotoxicity studies 
Cells in an exponential growth rate were seeded (10.000 cells per well) in 96-
well plates (Costar 3595) grown for 24 h in complete medium. Solutions of the 
gold compounds were prepared by diluting a stock solution (10-2 M in DMSO) 
of the corresponding compound in culture media (DMSO in the culture medium 
never exceeded 0.2%). Subsequently, intermediate dilutions of the compounds 
were added to the wells to obtain a final concentration from 0.5 to 100 μM. 
Following 72 h of exposure, 3 (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT/ Sigma-Aldrich, Steinheim, Germany) was 
added to the cells at a final concentration of 0.50 mg/ml in PBS (Phosphate 
buffered saline solution) and incubated for 2.5 h. The solution was removed and 
the violet formazan crystals were dissolved in DMSO. The optical density of 
each treatment was quantified in quadruplicate at 550 nm, using a multi-well 
plate reader (ThermoMax microplate reader, Molecular devices, US) and the 
percentage of surviving cells was calculated from the ratio of absorbance 
between treated and untreated cells. The IC50 value was calculated as the 
concentration inhibiting the cells growth by 50% and is presented as a mean (± 
SD) of at least three independent experiments. 
 
5.3.3 Preparation of rat Precision-Cut Tissue Slices (PCTS) and toxicity 
studies ex vivo 
Male Wistar rats (Charles River, France) of 250-300 g were housed under a 12 
h dark/light cycle at constant humidity and temperature. Animals were 
permitted ad libitum access to tap water and standard lab chow. All experiments 
were approved by the committee for care and use of laboratory animals of the 
University of Groningen and were performed according to strict governmental 
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and international guidelines. Kidneys were harvested (from rats anesthetized 
with isoflurane) and immediately placed in University of Wisconsin solution 
(UW, ViaSpan, 4°C) until further use. After removing fat, kidneys were cut in 
half using a scalpel. Cortex cores were made from each half using disposable 
6mm Biopsy Punches (KAI medical, Japan). Precision- cut Kidney slices 
(PCKS) were made as described by de Graaf et al.132,133 The cores were sliced 
with a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) in ice-cold 
Krebs-Henseleit buffer saturated with carbongen (95% O2 and 5% CO2). 
Kidney slices weighting about 3 mg (~150 μm thickness), were incubated 
individually in 12-well plates (Greiner bio-one GmbH, Frickenhausen, Austria), 
at 37°C in Williams’ medium E (WME, Gibco by Life Technologies, UK) with 
glutamax-1, supplemented with 25 mM D-glucose (Gibco) and Ciprofloxacin 
HCl (10 µg/mL, Sigma-Aldrich, Steinheim, Germany) in an incubator 
(Panasonic biomedical) in atmosphere of carbogen with shaking (90 times/min). 
Stock solutions of compounds (1, 2, 3, CDDP) were prepared as for MTT 
studies. The final concentration of DMSO during the PCKS incubation was 
always below 0.2% to exclude solvent toxicity. The slices were incubated for 
one hour in WME and subsequently, intermediate dilutions of the compounds 
were added to the wells, to obtain a final concentration from 0.5 to 50 μM. After 
the incubation, slices were collected for ATP and protein determination, by snap 
freezing them in 1 ml of Ethanol (70% v/v) containing 2 mM EDTA with 
pH=10.9. The viability of PCKS was determined by measuring the ATP using 
the ATP Bioluminescence Assay kit CLS II (Roche, Mannheim, Germany) as 
described previously.132,133 The ATP content was corrected by the protein 
amount of each slice and expressed as pmol/μg protein. The protein content of 
the PCKS was determined by the Bio-Rad DC Protein Assay (Bio-Rad, Munich, 
Germany) using bovine serum albumin (BSA, Sigma-Aldrich, Steinheim, 
Germany) for the calibration curve. The IC50 value was calculated as the 
concentration reducing by 50% the viability of the slices, in terms of ATP 
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content corrected by the protein amount of each slice and relative to the slices 
without any treatment, and is presented as a mean (± SD) of at least three 
independent experiments. 
 
5.4 Studies of interactions with DNA 
 
5.4.1 Materials  
The buffers used for the studies were phosphate buffer (PB, 50 mM, pH= 7.4) 
or a sodium cacodylate buffer (NaCac, 2.5 mM, pH= 7), prepared by dissolving 
the solid salts in MilliQ water. The pH was adjusted with NaOH or HClO4. 
Stock solutions of the compounds tested were prepared by dissolving a known 
quantity of the solid in DMSO. If necessary they were furtherly diluted in the 
suitable buffer. 
The DNA used was CT-DNA (calf thymus DNA) by Sigma-Aldrich, previously 
sonicated to 300 base-pair long polynucleotide (gel agarose test). Stock DNA 
solutions were prepared in ultra-pure water and, if necessary, furtherly diluted 
in the suitable buffer.  
Ultra-pure water was obtained through a Millipore S.A.670120 Mosheim 
apparatus. 
 
5.4.2 Instruments 
UV-Vis absorption spectra were recorded with a Perkin-Elmer Lambda 35 
double ray spectrophotometer.  
Spectrofluorometric spectra and titrations were conducted using a LS55 Perkin-
Elmer spectrofluorometer. To add the titrating solution to the sample a glass 
micro-syringe Hamilton equipped with a Mitutoyo micro-screw (minimum 
volume added 0,164 µl) was used. 
All spectra were recorded using quartz cuvettes of 1000 µl or 500 µl volume 
and an optical path of 1 cm. 
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Viscosimetric studies were performed on a Cannon viscosimeter using a semi-
micro Ubbelohde capillary, submerged in a water bath. Times of outflow were 
measured with a digital chronometer. Data were obtained as an average of three 
measures. 
 
5.4.3 Interaction of 13 with DNA 
Stability of the compound in aqueous solution was investigated by UV-Vis 
spectrometry. Absorption spectra at 25°C (λ = 230-480 nm) of a 5·10-5 M 
solution of 13 in PB or in PB with 5% DMSO were recorded every 5 min for 2 
h and 30 min, in a 500 µl quartz cuvette. Subsequently, 100 µl of a solution 
3.74·10-3 M of CT-DNA in MilliQ water was added to the solution of FG28 in 
PB with 5% DMSO. Absorption spectra were recorded. 
Secondly, fluorimetric properties of the compound were studied. Spectral 
parameters were optimized by recording excitation and emission spectra of a 
2.5·10-5 M solution of 13 in PB with 5% DMSO at 25°C (λex = 255 nm; λem = 
480 nm; slit= 5 nm). Spectra were recorded every 5 min for 2 h to investigate 
the stability of the signal. Subsequently, 50 µl of a solution 3.74·10-3 M of CT-
DNA in MilliQ water were added to the same solution and emission spectra 
were recorded at 25°C. In addition to this, fluorescence spectra of a solution of 
CT-DNA 1.87·10-4 M in PB with 5% DMSO were collected at 25°C. 
Moreover, emission spectra (λex= 255 nm; λem= 255- 490 nm) of 13 at various 
concentrations in PB with 5% DMSO were recorded at 25°C. 
Finally, fluorimetric titrations (λex = 255 nm; λem=  395 nm) of the compound 
(3.02·10-6 M in PB with 5% DMSO) with CT-DNA were carried out at different 
temperatures (9.9, 24.4 and 39.8 °C). 
 
5.4.4 Interaction of 4 with DNA 
Stability of the compound in aqueous solution was investigated by UV-Vis 
spectrometry. Absorbance spectra at 25°C (λ= 230-480 nm) of a 5.0·10-5 M 
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solution of 4 in PB or NaCac were recorded every 90 s for 2 h in a 1000 µl 
quartz cuvette. 100 µl of a solution 3.74·10-3 M of CT-DNA in MilliQ water 
were added to the solution of 4 in NaCac. Absorption spectra were recorded. 
A viscosimetric titration was carried out at 40°C: concentration of CT-DNA 
(CP) was kept constant (2.38·10
-4 M in NaCac) while the concentration of the 
compound (CD) varied in the range (CD/CP = 0-0.74). First of all, times of 
outflow of 2000 µl of the solvent or of CT-DNA with varying volumes (from 0 
to 400 µl) of a solution of DMSO 4.63·10-4 M in NaCac were measured. Then, 
measurements of times of outflow of a 2000 µl solution of CT-DNA with 
varying volumes (from 0 to 400 µl) of a 4.63·10-4 M solution of 4 in NaCac 
were carried out. 
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